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The unique properties of noble metal nanoparticles, which include tunable electronic and 
photonic characteristics, contribute to their potential as novel delivery vectors with enhanced 
drug stability, cell uptake, and photo-activated functionalities. Silver, as one of best surface-
enhancing substrates available for bulk nanostructure synthesis, is a prime choice for 
investigations of metal nanohybrids as antisense therapy vehicles with special surface plasmon 
resonance (SPR) enabled functional attributes. The singular photonic properties of silver 
nanoparticles (SNPs) may contribute to ease of delivery confirmation and in situ photo-activation 
of protected cargo packed on particle surfaces. Here we show the synthesis and characterization 
of 40-80nm SNPs designed for enhanced antisense oligonucleotide delivery and photo-activated 
gene silencing. Non-active (caged) SNP-bound DNA oligonucleotides possess an internal 
nitrobenzyl photocleavable linker which once exposed to light, initiates disengagement of 
functional antisense oligonucleotides from the nanohybrid surface. We demonstrate light-
triggered, spatiotemporally controlled gene silencing based on SNP-antisense conjugates, which 
prove to be promising alternative platforms for gene therapy, gene expression studies, and other 




Chapter 1. Background and Significance  
1.1 Objectives 
The objectives of the current thesis project are as follows: 
1. Synthesize and characterize 50-60nm diameter citrate-stabilized silver nanoparticles (SNPs)  
a. Evaluate SNP morphology, yield, and optical properties 
2. Functionalize SNPs with thiol-modified antisense oligonucleotides possessing internal photo-
cleavable (nitrobenzyl) linkers 
a. Evaluate size, morphology, and yield of functionalized SNP-oligo conjugates 
b. Quantify oligonucleotide attachment to SNP-antisense conjugates 
3. Evaluate o-nitrobenzyl linker photochemistry on silver nanoparticle surfaces 
 
4. Evaluate the intracellular delivery of SNP-antisense conjugates and photo-induced release of 
antisense oligonucleotides within an adherent epithelial cell line 
a. Evaluation of antisense functionality against intracellular adhesion molecule-1 
(ICAM1) of SNP-antisense photo-activated conjugates within HeLa cells 
1.2 Noble Metal Nanoparticles: Properties and Applications  
 The use of nanostructures, notably colloidal nanoparticles, in molecular diagnostics and 
drug delivery has emerged and increased significantly within the last decade[1]. Nanostructures 
are amenable to molecular detection, intracellular diagnostics and therapeutic applications due to 
their sub-microscopic dimensions (<1 um) and the often unique properties which emerge at these 
dimensions, and which differ from those of the bulk materials. Due to corresponding size-scales, 
nanostructures easily interface with biological molecules, such as nucleic acids and proteins[1] 
(Figure 1-1). Among the nanostructures which are increasingly being used as biological sensors 
and delivery vehicles for therapeutic agents, nanoparticles are of particular interest. While the 
material makeup of nanoparticles used in biomedical applications are diverse, this project will 
focus on the semiconductor and noble metal materials. Beneficial characteristics of such 
nanoparticles include tunable size, shape, and functionality attributes; relative ease of fabrication 
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via „wet chemistry‟ techniques[2]; large surface area-to-volume ratio; simple surface 
functionalization (via sulfur-metal linkages on noble metal nanoparticles) [3-4], and enhanced 
stability of attached macromolecules such as nucleic acids[4-5]. 
Semiconductor and metal nanoparticles, typically in the range of 1-100nm in diameter, 
are attractive due to their unique electronic and photonic properties [2, 6-7]. Small 
semiconductor (commonly ZnS, CdS, CdSe) nanoparticles, known as quantum dots, have met 
with tremendous success as biological labels, due to their tunable fluorescent properties[8].  
Noble metal (Au, Ag, Pt, and Cu) nanoparticles have accrued interest owing to a phenomenon 
unique to these nanomaterials, known as localized surface plasmon resonance (LSPR). LSPR 
occurs when a small spherical metal particle is subjected to an oscillating electric field, which 
causes the conduction electrons at the metal surface to oscillate collectively in response[7]. The 
local field enhancements attributed to surface plasmons have paved the way for many surface-
enhanced spectroscopy techniques, including surface-enhanced absorption, fluorescence, 
photochemistry, and Raman scattering (SERS)[9]. These techniques have applications in 
chemistry, biology, and medicine.  
Gold (Au) and silver (Ag) nanoparticles have been used extensively as biological sensors 
which take advantage of plasmon resonance to enhance detection of specific targets. Noble metal 
nanoparticle-based sensors benefit from the extreme sensitivity of the localized surface plasmon 
resonance (LSPR) spectra to environmental changes[10]. Application of metal nanoparticles is 
not limited to molecular detection: recently, gold nanoparticles (GNPs), and to a lesser extent 
silver nanoparticles (SNPs), have been harnessed as delivery vehicles for therapeutic agents, 
including antisense oligonucleotides[11-13] and other small molecules[4, 14-15]. Small metal 
nanoparticles offer many advantages as drug carriers, including high-density surface ligand 
3 
 
attachment, transmembrane delivery without harsh transfection agents[11], protection of the 
attached therapeutic from degradation[5, 12, 16], and potential for improved timed/controlled 
intracellular release[16]. The photophysical properties of noble metal nanoparticles[17] may 
potentially bring these materials to the forefront of drug delivery, enabling targeted delivery, 
spatiotemporally controlled (photo-)release, and delivery confirmation via imaging.  
 
Figure 1-1 - Nanoparticle-Biomolecule Hybrids  
(based on figure from Katz, Angew. Chem., Int. Ed. 2004, 43, p.6042) 
 
1.2.1 Localized Surface Plasmon Resonance (LSPR) 
 Localized surface plasmons (LSPs) are excitations of the conduction-band electrons of 
sub-wavelength conductive nanoparticles coupled to an incident electromagnetic field (i.e. 
light)[18]. Whereas noble metals in bulk form have overlapping conduction and valence electron 
bands, metal nanoparticles, consisting of a number of electrons large enough to be characterized 
by properties differing from those of single atoms, yet too few electrons to reflect the properties 
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of the bulk metal, have close lying (not overlapping) conduction and valence bands between 
which electrons to move relatively freely based on their energy state[17] (Figure 1-2). Surface 
plasmons are based mostly upon the oscillations of free electrons within the conduction band that 
occupy energy states immediately above the Fermi level[17, 19], where the Fermi level is the 
outer boundary of electron energy states at absolute zero temperature. Electrons which exist in 
energy sates above the Fermi level are available for conduction. The optical properties of noble 
metal nanoparticles are mostly influenced by the said electron oscillations, however, the 
movement of bound electrons can also contribute to the plasmon spectra of these resonant 
particles[7]. Localized surface plasmon resonance (LSPR) occurs as the charge-density 
oscillations of the conduction electrons on the surface of metal nanoparticles[6] attain resonance 
conditions. Resonance modes arise due to the fact that the curved surface of the nanoparticle 
exerts an effective restoring force on the oscillating electrons[18]. Under resonance conditions, 
the nanoparticle acts as an electric dipole, resonantly absorbing and scattering electromagnetic 
fields[18]. In 1908 Mie applied Maxwell‟s equations to sub-wavelength conductive spheres (Mie 
Theory[19]) in order to describe the optical properties of metallic nanoparticles. Mie theory 
describes and quantifies the extinction spectra (the combination of absorption and scattering) of 
spherical particles of arbitrary size in various dielectric media[7]. Since the advent of Mie theory, 
other models have been developed to further and more precisely describe the electronic 
properties of metal nanoparticles, especially non-spherical particles[20]. However, Mie theory 
remains an important model for describing the size-dependent optical properties of spherical 
particles in solution. 
 Localized surface plasmons (LSPs) effect strong absorption and scattering of light. This 
phenomenon is the underlying cause of the bright colors observed in solutions of colloidal noble-
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metal nanoparticles. Gold (Au) and silver (Ag) nanoparticles have properties such that their 
plasmon resonant absorption spectra lie within the visible region[17]. Colloidal Au nanoparticles 
are characterized by a wine-red color, with a plasmon band centered around 520nm[21]. 
Colloidal Ag nanoparticles are characterized by a yellow/green color, with a plasmon band 
around 400-420nm dependent on particle size[22]. The plasmon frequency of these particles 
depend on particle size, shape, surface state, interparticle distance, and the surrounding dielectric 
environment[6], as well as adsorbed species on the particle surface. The plasmon frequency 
dependence on interparticle distance has been utilized in colorimetric assays to determine 
hybridization-induced coupling of DNA-functionalized gold and silver particles[10, 23-24]. The 
plasmon frequency dependence on particle size and shape has lead to tailoring of nanoparticle 
photophysical properties for specific applications via various synthesis methods and 
conditions[25].  
 According to Mie Theory, the extinction cross-section (Cext) of metal nanoparticles is 
comprised of both absorption (CA) and scattering (CS) components. For small metal particles (λ 
>> 2R where R is the particle radius), the extinction cross-section is dominated by dipole 
oscillations at the particle surface[26-27], leading to a dipole approximation of extinction based 








 𝜺𝟏 𝝎 + 𝟐𝜺𝒎 
𝟐+𝜺𝟐(𝝎𝟐)
𝟐
       1 
      
where V is the spherical particle volume, c is the speed of light, ω is the angular frequency of the 
incident light, εm is the dielectric constant of the surrounding medium, ε1 and ε2 are the real and 
imaginary parts of the dielectric function of the particle metal, respectively, where εparticle = ε1(ω) 
+ iε2(ω). The optical extinction reaches a maximum amplitude at the plasmon resonance 
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condition, or when ε1(ωres) ≈ -2εm. The plasmon resonance frequency describes the location at 
which absorption and scattering (both components of extinction) of light by metal nanoparticles 
are at a peak value based upon maximum amplitude of electron oscillations and interactions. The 




, which may 
be compared to the cross-section of fluorescein, a standard strongly absorbing and bright 




[28]. The strong optical properties of metal 
nanoparticles compared to other well-known chromophores increases interest in their use in light 
scattering and surface-enhanced spectroscopy applications. 
For larger nanoparticles (2R comparable to incident wavelength λ) the dipole oscillation 
mode is joined by higher multipole modes. The sum of these plasmon modes are described by 
the more robust complete Mie theory. For small nanoparticles, the absorption component of 
extinction predominates, based on nonradiative processes of plasmon decay[29]. As metal 
nanoparticles increase in size, the scattering component begins to contribute significantly to the 
total extinction, based on radiative emission of electromagnetic energy by the surface 
plasmon[29]. Thus, for applications where strong scattering of incident light (radiative coupling 
to outgoing electromagnetic field[29]) is desired, such as for surface-enhanced fluorescence or 
photochemistry, the use of larger metal nanoparticles (2R > 30nm)[6-7] may be beneficial. As 
previously stated, surface plasmon resonance frequency is largely dependent on particle size, and 
larger particles, dominated by multipole absorption and scattering, typically exhibit red-shifted 
(longer wavelength) extinction spectra[26]. As a result of these phenomena, the extinction 
spectra of metal nanoparticles, their absorption and scattering properties, may be tailored via 




Figure 1-2 – Overlap of conduction and valence electron bands for metals: single atom, 
nanoparticles, and bulk metals 
 
1.2.2 Surface-Enhanced Spectroscopy and Photochemistry 
Localized surface plasmons effectively confine incident light into sub-wavelength 
(nanometer-scale) dimensions[30]. This condensing of incident light produces large local 
enhancements of electromagnetic fields. Along with E-field enhancement, enhanced absorption 
and scattering of light by nanoparticles at the surface plasmon resonance (SPR) frequency are 
observed [27, 29]. The special electronic properties of metal nanoparticles and the influence of 
these electronic properties on molecular species on or near the particle surface constitute the 
basis of surface-enhanced spectroscopy techniques. These include surface-enhanced absorption, 
surface-enhanced Raman spectroscopy (SERS), surface-enhanced fluorescence (SEF), and 
surface-enhanced photochemistry[9]. The amplification or quenching of signals near a metal 
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nanoparticle surface arises due to a concentration and enhancement of electromagnetic energy in 
the region of space on and just outside the metal sphere surface[9, 31]. Enhancements in 
absorption, fluorescence, and Raman scattering can be based upon enhancement of absorption 
processes of compounds near the metal surface, provided that the molecular absorption bands for 
the compounds in question are close in frequency to the SPR frequency of the metal particles[9, 
32]. Alternatively, enhancement of emission processes from excited chromophores near the 
surface of metal nanoparticles may be responsible for overall enhancement of fluorescence[33] 
and luminescence signals. The surface-enhanced resonance Raman scattering (SERRS) 
technique, often used for sensitive single-molecule detection, is based upon the fact that Raman-
scattered light, thus detection signals, can be significantly magnified by adsorbing target 
molecules onto roughened metal surfaces or metal nanoparticles[34]. Surface-enhanced 
fluorescence (SEF) on silver (Ag) particles and films has been observed and extensively studied. 
SEF, as well as most other surface-enhanced spectroscopy processes, is dependent on particle 
size[31] and on distance between target molecules and the metal particle surface, where 
emissions from molecules directly on the metal surface are often quenched vs. enhanced.  
In addition to the enhancements of Raman scattering, light absorption, and fluorescence 
observed as result of interaction of molecular targets with metal nanoparticles, enhanced 
photochemistry has been predicted[35-36] due to observed increases in molecular absorption 
cross-sections of photo-responsive molecules near metal surfaces (thin films[37], rough 
surfaces[36, 38], and nanoparticles[39]). Surface-enhanced photochemistry[32] has potentially 
significant applications in chemistry and biology[9], of note for the studies proposed herein, 
whereby photo-catalyzed reactions and photo-induced release of therapeutics from metal 
nanoparticles will be characterized. Surface-enhanced photochemistry may yield unique 
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pathways for photoexcitation and photoreaction[32], with a wide range of applications. Reports 
have been made of enhancements of photo-induced reactions of aromatics adsorbed on silver 
surfaces (rough metal and nano-scale surfaces), as well as enhancement of 2-photon 
decomposition[36]. Although surface-enhancement of photochemistry has been predicted and 
observed in various cases, proximity to a metal nanoparticle surface may in some cases serve to 
quench photochemical reactions, as predicted by Nitzan et al[35]. However, many reports of 
generation of excited states in photoreactive moieties on metal nanoparticles sufficient to effect 
photo-induced chemical reactions[17, 40] provide promising evidence for the potential of 
surface-enhanced photochemistry. 
The enhancement factor of photochemistry at or near a metal surface, related to enhanced 
absorption and excitation, will depend on particle shape and size, as well as the distance of the 
photoactive molecule from the particle surface[36]. The size factor, as depicted by results 
produced by Zhang et al in studies on field-enhancement by silver nanoparticles[31], will be 
considered in proposed studies for the choosing of appropriate SNP sizes for maximum 
enhancement of photochemical processes. Moderately sized particles (around 50nm in diameter) 
have been found previously to display the most enhanced intensity of local fields and SEF[31]. 
The distance factor is of particular importance in relation to photochemical processes of 
molecules directly adsorbed or tethered a short distance from the metal surface (<1nm), where 
the energy-transfer rate to the metal surface surpass the photochemical reaction rate. In such 
cases, the effective transfer of energy from the excited molecule to the metal surface competes 
with the enhanced accumulation of energy by the molecule due to interaction with surface[41], 
thus quenching the molecule‟s excited states. Thus an important consideration in surface-
enhanced photochemistry will be tailoring the distance of a photoactive molecule/functional 
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group from the metal nanoparticle surface, in order to strike a compromise between field 
enhancement (i.e. enhanced photochemistry) and nonradiative damping[9] or quenching.  
1.2.3 Optical Properties of Silver Nanoparticles 
 Gold (Au) and silver (Ag) nanoparticles in the diameter range of ~2-100nm exhibit SPR 
spectra in the visible region, which are tunable and dependent on particle shape, size, 
environment, and interparticle distance. While gold nanoparticles have been used extensively in 
many of the applications previously discussed, silver nanoparticles have unique properties which 
make them a desirable alternative particle type in many cases. Silver nanoparticles (SNPs) are 
the strongest light scatterers of the noble metal particles[22, 42]. The intense light absorption and 
scattering (extinction) band of silver nanoparticles (~380-420nm dependent on particle size) is 
due primarily to free conduction electron oscillations, although bound electron movements also 
contribute to the optical spectra[22]. The light scattered by an Ag colloid has the same 
wavelength of the incident light, as electrons emit only by transition to their original ground 
state[22], vs. relaxing into other vibrational states before returning to their ground state (process 
of fluorescence). Thus enhancement of absorption/emission of light by molecules near the silver 
particle surface is dependent on particle size and proximity or overlap of the resonance (SPR) 
spectra with the absorption/emission bands of the molecular species.       
 The light absorption and scattering properties for silver nanoparticles of different sizes 
have been calculated in accordance with Mie Theory[19, 22] (Table 1-1). For larger particle sizes 
(~50-60nm) as will be seen in the current studies on SNPs for nucleic acid delivery and photo-




            2 
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Where values >1 indicate the ability of a particle to scatter photons outside its physical cross-
sectional area[22]. Thus silver particles in this size range may scatter light (as well as enhance 
electromagnetic fields) at or above the physical metal surface. The scattering cross section of a 
silver particle is about 10 times greater than that of a gold particle of the same size[22]. Silver 
nanoparticles in the diameter range of 40-70nm (Table 1-1) achieve high scattering efficiencies 
while maintaining surface plasmon resonance in the UV to visible range appropriate for 
traditional and red-shifted photocleavable compounds typically used as photo-caging 
compounds.  
 The light-scattering and field-enhancement properties of silver nanoparticles have led to 
an increased interest in their use as sensors, biological labels, and substrates for surface-
enhanced absorption, fluorescence, and photochemistry. Enhanced photochemistry has been 
predicted on silver surfaces, and silver nano-materials comprise the best enhancing substrate 
found to date[35]. Silver nanoparticles have high extinction coefficients[22, 36] along with low 
SPR frequencies (near-UV range) which make these particles particularly appropriate for studies 
of enhanced photochemistry of photoreactive moieties sensitive to UV irradiation.  





1.2.4 Nanoparticle Synthesis 
 A variety of methods are available for the production of nanoparticles within a specified 
size distribution[2]. These include reduction of metal ions via chemical capping agents to form 
metal nanoparticles in solution, vacuum deposition, electron-beam (EB) lithography, laser-
ablation (photo- and radio-lytic reduction of metal ions), and electrodeposition (electrochemical 
deposition of nanoparticles)[6]. Spherical noble-metal nanoparticles for applications such as 
delineated herein are commonly prepared via „wet chemistry‟ procedures, where „clusters of 
metal atoms… are formed in the presence of a surface-capping ligand‟[2]. The capping 
ligand[2], whether a hydrophobic ligand, a charged ligand, or a polymer stabilizing agent, serves 
to stabilize individual nanoparticles and prevent aggregation via particle-particle repulsion. The 
wet chemistry synthesis procedures are often simple and practical in the tunable synthesis of 
spherical particles of sufficiently narrow size distribution.  
 Au and Ag nanoparticle colloids are often prepared via reduction of metal ions (reaction 
of HAuCl4 or AgNO3 in aqueous solution) via sodium borohydride, (NaBH4) or trisodium 
citrate[25, 43]. The ratio of capping agent to metal in solution during reduction may be varied to 
achieve a desired size distribution (where higher a high ratio of capping agent to metal will 
produce smaller particles). Reduction with citrate has been reported to produce colloids with 
more uniform size distributions, greater stability in solution over time, and more pronounced 
surface-enhanced optical properties than colloids synthesized via borohydride-reduction[44]. 
Nanoparticles formed via citrate-reduction are coated by negatively charged electrical double 
layers which provide stabilization of individual Au or Ag nanoparticles[6]. Wet chemistry 
synthesis of silver and gold nanoparticles via citrate-reduction has been adopted herein due to 
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ease of synthesis and simple replacement of capping ligand (citrate) with thiol-modified 
biomolecules at the particle surface (Figure 1-3). 
 
Figure 1-3 - Citrate-stabilized SNP functionalization with thiol-modified biomolecule (DNA) 
 
1.2.5 Nanoparticle Characterization 
 A myriad of techniques exist for the characterization of metal nanoparticles. The optical 
properties of noble metal nanoparticles may be determined theoretically[20, 22] and 
experimentally via UV-Visible spectroscopy and microscopy techniques[42]. Particle 
morphology, including shape and size, may be determined to some extent via spectroscopy 
techniques using the fact that shape and size affect SPR spectra, but are more often determined 
via electron microscopy techniques[42].   
1.2.5.1 Characterization Technique: TEM 
 
TEM (Transmission electron microscopy) is an analytical tool for determining the shape, 
size, and arrangement of nanomaterials. TEM produces images based upon electron interactions 
with a thin sample specimen, where more or less dense regions of the specimen produce the 
imaging contrast portrayed by the final photographic films. Several studies have utilized TEM as 
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a characterization method for different nanoparticles, including SNPs[45]. TEM will serve as a 
characterization tool herein, in order to determine morphology and size distribution of citrate-
reduced silver colloids.  
1.2.5.2 Characterization Technique: UV-Visible Spectroscopy 
UV-visible spectroscopy is a very simple and quick method for characterizing colloidal 
metal nanoparticles based upon their optical (light-absorption) properties. It is not an ideal 
technique for providing detailed information regarding NP shape and size distribution when 
compared to microscopy-based analysis techniques, but is a semi-quantitative method for 
determining the presence, approximate size, and extent of aggregation of nanoparticles in 
solution. The determination of such is based upon the plasmon resonant properties of the metal 
nanoparticles. The bandwidth, peak height, and maximum absorption of a UV-Vis spectra for a 
particle colloid are dependent on individual particle size, size distribution (bandwidth), surface 
state, surface coverage (can induce blue- or red- shifting of spectra), interparticle distance, and 
surrounding dielectric environment[6]. Absorbance spectroscopy can also serve as an indicator 
of material deterioration and is a qualitative method for indicating whether a given colloid is still 
within its usable lifetime for biomolecule functionalization. Absorbance spectroscopy has been 
carried out herein using an LS55B Luminesence Spectrophotometer (Perkin Elmer, Boston, 
MA). 
1.2.5.3 Characterization Technique: Dynamic Light Scattering 
 Dynamic light scattering (DLS) is a technique by which the size distribution of small 
particles in solution (a colloid)  may be quantified from changes in a light field (frequency shifts, 
polarization changes) due to its interaction with the colloidal  system[46].  The information 
gathered by DLS is related to the light scattering properties of suspended solutes. Dynamic light 
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scattering may be used to measure the diffusion coefficient for solute molecules/particles, which 
is related to the radius of a spherical molecule/particle (Stokes Einstein equation):  
𝑫 =  
𝒌𝒃𝑻
𝟔𝝅𝜼𝒓
            3 
    
Where 𝑘𝑏  is the Boltzmann constant (in J K
-1




) and T is 
the temperature in Kelvin, and r is the hydrodynamic (or Stokes) radius. The hydrodynamic 
radius is the apparent radius of a molecule/particle in solution, based on their measured rates of 
diffusion. Dynamic light scattering analysis of a colloid also provides a measure of the 
polydispersity (size distribution) of the particle solution. 
 Dynamic light scattering instruments may also be used to measure zeta potential 
(electrokinetic potential at the effective shear plane between the moveable and non-moveable 
part of the double layer[47]) of colloids. Zeta potential of solutes may be determined from the 
light scattering properties of molecules/particles moving within an applied electric field  
(electrophoretic light scattering)[47]. Zeta potential is an important indication of colloid stability 
and biomolecule adhesion onto the particle surfaces. DLS will been performed herein using a 
Malvern ZetaSizer Nano ZS (Malvern, Worcestershire, UK). 
1.3 Metal Nanoparticle Functionalization with Biomolecules: Nanohybrids 
 
 Recent advances in metal nanoparticle synthesis and functionalization with various 
organic compounds, including proteins, nucleic acids, long-chain hydrocarbons, have led to 
increasing applications of noble metal nano-hybrids in biology and medicine. These nano-
hybrids incorporate the bioactive properties (catalytic functions, recognition and binding 
properties) of macromolecules with the unique optical and photochemical properties of noble 
metal nanoparticles[2]. The relative ease of noble metal nanoparticle functionalization stems 
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from a variety of means for immobilizing biomolecules on the metal surface. These include 
electrostatic interactions as well as covalent binding[2]. Metal nanoparticles that are synthesized 
by salt reduction are in most cases stabilized by anionic ligands such as carboxylic acid 
derivatives[2] (notably citrate), which give the metal particles a net negative surface to stabilize 
the particles and prevent particle-particle interactions (aggregation). The negative surface allows 
electrostatic interactions of cationic ligands/functional groups with the metal particle surface, for 
example the positively charged amino acid side chains of proteins[2]. Predominantly, 
functionalization of metal nanoparticles is achieved via covalent coupling of biomolecules to the 
metal surface. The binding of thiols to the metal surface (via covalent sulfur-metal bond), is a 
predominant method of nanoparticle functionalization[2]. Amine and carbonyl functional groups 
may also interact with the metal surface[48] and serve to tether biomolecules to the nanoparticle 
surface using standard conjugation chemistries.    
 The functionalization of metal nanoparticles with nucleic acids is of particular interest in 
the current studies. Nucleic acid-nanoparticle hybrids have been used for a variety of 
applications, including DNA detection based on LSPR absorbance changes[6, 49], particle 
assembly based on hybridization[10, 21, 23-24], DNA intracellular delivery[3-4, 11, 15, 50], and 
gene therapy[12-13]. Nucleic acids are typically immobilized on metal nanoparticles via covalent 
coupling (thiol end-modified nucleic acids). The nucleotide bases of single-stranded DNA 
(ssDNA) are also available for binding to the metal surface via amine and carbonyl functional 
groups[48, 51]. Double-stranded DNA (dsDNA), however, generally does not interact with 
anionic ligand stabilized nanoparticles due to repulsive forces between the negatively charged 
particles and the phosphate backbone of the DNA (Figure 1-4). In cases where thiol linkage of 
nucleic acids is desired over „nonspecific‟ base interactions with the metal surface[49, 52], 
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techniques must be employed to create an environment where sulfur-metal bonds are favored 
over other interactions. Thiol linkage predominance serves to increase surface coverage due to 
tight packing of ligands on the particle surface. Such techniques will be investigated in the 
proposed studies on antisense oligonucleotide functionalized silver nanoparticles.  
 
Figure 1-4 - Nucleic acid interactions with metal nanoparticles 
 
1.3.1 SNP Functionalization with Nucleic Acids 
 Metal-biomolecule nano-hybrids are often developed by assembling single molecule 
monolayers, or mixed monolayers (assembling a monolayer of one type of biomolecule and 
backfilling with another), on the nanoparticle surface via functional groups which interact with 
metal, such as thiols, amines, carbonyls, etc[53]. Oligonucleotides may be end modified with 
thiol functional groups in order to assemble a tightly-packed monolayer of nucleic acid on a 
nanoparticle surface. Following thiol adsorption to the metal surface, the nucleic acids will 
ideally be oriented perpendicularly to the surface. Oligonucleotide bases also have intrinsic 
reactive functional groups (significantly amines) which have the tendency to associate with metal 
surfaces. While these „non-specific‟ interactions are not desired in the final nanohybrids, they 
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may serve to stabilize SNP-oligo conjugates in the early stages of functionalization[52]. 
Typically nanoparticle-nucleic acid conjugates must be slowly adjusted to physiological salt 
concentrations (≈ 150 mM), conditions which serve to minimize the electrostatic repulsion 
between individual oligonucleotides („screening effect‟)[54] that arises due to the negatively 
charged state of the phosphate backbone. This screening will enhance surface coverage[10, 52, 
55-56], as well as create an environment at the particle surface most favorable to ligand 
attachment via thiol bonding vs. amine, carbonyl, or other functional group interactions. The 
screening effect will also apply to the negatively charged (citrate-stabilized) nanoparticle surface, 
and without the presence of a stabilizing layer of biomolecules, will effect irreversible 
aggregation of the colloid[10, 51]. Thus the required level of salt (typically NaCl) must be added 
gradually, and a fine balance must be struck in order to maximize surface coverage as well as 
colloid stability. Nanoparticle size (curvature)[57], oligonucleotide length and sequence[48], 
presence of „linkers‟ or spacers molecules, presence of low levels of surfactant[56], and final salt 
concentration have all been found to affect surface coverage and stability of SNP-oligo 
conjugates.  
1.3.2 SNP Functionalization: Solutions for a Difficult Process 
The functionalization of silver nanoparticles has been found to be exceptionally difficult, 
and requires delicate equilibration to final salt concentration, or „salt-aging‟[10], and often 
special design of attachment moieties[58]. Functionalized SNPs are typically unstable and prone 
to chemical degradation[59]. Gold nanoparticles are not as sensitive, which has led to the more 
widespread use of these particles in sensing and medical applications. However, as previously 
described, silver nanoparticles have special properties which make them highly desirable as an 
alternative to gold nanoparticles in many applications. Thus the optimization of silver 
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nanoparticle functionalization, and the development of novel methods for increasing colloid 
stability during functionalization and salt addition are desired. Such methods include the use of 
mild surfactants such as sodium dodecyl sulfate (SDS) or Tween 20 during the „salt-aging‟ 
process[48], and according to a method developed herein the use of a small amine-containing 
molecule, Tris, which interacts with metal surface. Tris(hydroxymethyl)aminomethane (Tris) is a 
compound often found in buffer solutions for nucleic acids. Although the presence of Tris during 
nucleic-acid attachment to metal surfaces has been shown previously to not significantly affect 
ligand coverage on gold nanoparticles[56], a custom Tris buffer-based functionalization method 
has been shown to dramatically enhance silver nanoparticle-conjugate stability during 
functionalization, as well as produce high oligonucleotide surface coverage. This has far-
reaching implications in silver nanoparticle functionalization, and may serve to broaden SNP-
biomolecule conjugates applications in biotechnology and medicine. 
1.4 Nanoparticles as Drug Delivery Vehicles 
 Functionalized metal nanoparticles have accrued significant interest as drug delivery 
vehicles and potential substrates for targeted and controlled release of therapeutic agents in vivo. 
Protein-based and, of interest herein, nucleic acid-based drugs are in need of novel delivery 
technologies which can enhance delivery, prolong lifetime, enable precise targeting, improve 
efficacy, and minimize side effects[16]. Nanoparticles provide a promising and exciting solution, 
bringing to the table improved delivery and stability characteristics, as well as the potential for 
external control (thermal, photo-thermal[4], light-activated[60]) over drug release and activity in 
vivo[16]. Various nanoparticle formulations have been used for delivery of biomolecules such as 
small molecule therapeutics[14, 16, 61-62], proteins[16, 62], and nucleic acids[3, 11-13, 15-16, 
50, 63]. Nanoparticles have been shown to protect immobilized biomolecules from degradation 
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(notably nucleic acids[5]), thus prolonging their active lifetime[16]. Protection of nanoparticle-
immobilized nucleic acids from degradation by nucleases has been partially attributed to the high 
local salt concentration which accompanies dense nucleic acid packing on the particle surface. 
High salt concentration is known to deactivate the enzymatic activity of DNase II[64], a 
principal agent of nucleic acid degradation in vitro. Other explanations for the stability of nucleic 
acids when attached to nanoparticles include steric hindrance of nucleases, protection of a 
surface-attached 3‟ oligonucleotide end from 3‟ exonucleases[65], and possible protective layers 
of positively-charged serum proteins which absorb to the highly-charged nucleic acid-
nanoparticle surface[11]. 
Biomolecule surface-functionalized nanoparticles not only possess characteristics of 
enhanced stability, but provide a means to deliver greater amounts of target therapeutic via high 
density surface coverage, often without requiring additional transfection agents for passage 
through the cell membrane[11]. Backfilling of a nucleic-acid functionalized nanoparticle with 
lipid or polymer species (for example polyethylenimine or PEI) often used for gene delivery can 
further enhance transfection efficiency beyond that of lipid or polymer transfection agents 
unattached to nanoscale carriers[4, 66]. Nanoscale delivery vehicles have been shown to enhance 
cellular uptake via facile endocytosis of small functionalized nanoparticles[62], intracellular 
trafficking of delivered therapeutics, and nuclear access[67], the later being an important process 
in gene expression based therapies. Beyond the their enhanced cellular uptake and their delivery 
of high drug concentrations, metallic nanoparticles are also attractive due to the possibility of 
controlling the release of the bound therapeutic molecules from the particle surface. The ability 
to attach ligands via specific interactions to the metal nanoparticle surface offers a high degree of 
engineering precision[16] with the potential for ligand/receptor targeted delivery[15] and 
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controlled release of the particle payload. Controlled release mechanisms of drugs from 
nanomaterial surfaces have included thermal, pH, chemical, and ionic strength stimuli based 
processes. The optical and photophysical properties of metal nanoparticles further provide 
unique prospects for photo-controlled release and characterization of delivery and release based 
on SPR-enhanced imaging signals. 
1.5 Photo-controlled Release 
Light-responsive systems are of great interest in the field of drug delivery and gene 
therapy, owing to the capability of external, spatiotemporal control (in time and location) over 
the delivery and activation of therapeutics coupled with such systems. Light-responsive drug 
delivery systems are triggered by electromagnetic radiation, typically in the UV, visible, and near 
infrared (NIR) range[68]. These systems are based upon photosensitive compounds which can be 
incorporated into a drug delivery vehicle, or coupled to the drug itself („caging‟ compounds), and 
may switch to an active or inactive state upon electromagnetic irradiation within a specific 
frequency range. Caged compounds, „whose activities are suppressed by the covalent linkage of 
photocleavable protecting groups but are restored upon photo-irradiation‟ are powerful tools for 
spatiotemporal control over drug activity in living systems[69]. Photocleavable groups have been 
used to cage, or inactivate, various biomolecules, including nucleotides, proteins, and nucleic 
acids[69-71], for the purpose of controlled, on-site photo-activation. Uncaging via light 
irradiation allows rapid, spatially and temporally defined release of a biomolecule at intended 
tissues or even within a specific intracellular compartment[69].  
1.5.1 Potential of Nanoparticle-Based Caged Compounds 
Caging of nucleic acids has been employed for many applications in biology and 
medicine, including controlled delivery, gene therapy, and analysis of gene expression[72]. 
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Nucleic acid drugs depend on hybridization-based function, thus caging of sites along an 
oligonucleotide (backbone phosphates, base functional groups) which prevent hybridization to a 
complementary oligonucleotide effectively inactivate these therapeutics. While the caging of 
nucleic acids for light-activated release and gene therapy has been achieved by a variety of 
methods, mostly via direct modification of nucleic acids with photo-labile protecting groups 
which prevent base-pairing with a complementary sequence[69-71, 73], recent interest lies in the 
use of nanoparticles as „bulky‟ caging groups, which can suppress the activity of „cargo‟ 
biomolecules until release of the later from the nanoparticle surface, as demonstrated by 
Nakanishi et al in the release (uncaging) of histamine from gold nanoparticles[74]. The dense 
packing of nucleic acids on metal surfaces has been shown to not only enhance stability of 
nucleic acid therapeutics by preventing nuclease degradation[5], but also reduce hybridization 
via steric and electrostatic hindrances[52]. Nanoparticles with photo-responsive moieties may 
provide enhanced external control over intracellular release and activation of cargo 
therapeutics[68], while also providing a solid support for enhanced stability and delivery of these 
therapeutics[74] prior to on-site release. Photo-responsive nanoparticles, consisting mostly of 
gold and other metal or semiconductor materials, have been used in the delivery and 
spatiotemporal activation of anticancer drugs[14, 61], cell signaling molecules[74], and nucleic 
acids[60].  
While increased interest has arisen in the use of nanoparticles as delivery vehicles, 
controlled release of DNA from surfaces is a relatively unexplored area[75], albeit a promising 
one. Controlled release of nucleic acid therapeutics in functional form from solid-surface 
carriers, which may enhance stability, delivery, imaging, and provide sensitive external control, 
is of great interest in gene therapy[75]. Release of nucleic acids from surfaces (including 
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nanoparticle surfaces) via thermal, pH[76], ionic strength, and chemical stimuli[77] have been 
reported, but the integration of photoresponsive units into such systems offers the capability for 
regulated release with higher spatiotemporal specificity. Properties which define good caging 
systems include high rate of release following photo-exposure, precise focusing of release 
location based upon ability to focus incident light (focusing at organ, tissue, cellular, or sub-
cellular compartment levels[69]), external control over time of release and activation of 
delivered therapeutics, and tunable amount of release based upon degree of light exposure[69]. 
The design of a good caged system must take into account the following ideals: high absorption 
and quantum yield properties of the activating photochemical reaction, harmless byproducts, a 
water soluble form capable of being easily delivered across the cell membrane, a low level of 
activity („leaking‟) prior to photoactivation, and photoreactivity at wavelengths above 300nm, 
considering the damaging effects of lower wavelength light on biological tissues and DNA itself. 
Noble metal nanoparticles are presented as a potentially superior alternative to traditional carrier 
vehicles and caging systems, providing ameliorated delivery properties as compared to naked 
nucleic acids or other transfection agents alone[16, 66] and the potential of surface-enhanced 
photochemistry, including enhanced absorption and potentially enhanced photocleavage at SPR 
peak wavelengths (~400-420nm for silver nanoparticles). Nanoparticle-assisted photocleavage of 
traditional caging compounds at higher wavelengths than the traditional UV-range (300-350nm) 
would be of enormous interest in drug delivery and gene therapy. In recent years efforts have 
been made to create photolabile protecting groups with enhanced photoreactivity at red-shifted 
wavelengths, for example modified 2-nitrobenzyl derivatives with enhanced one-photon and 
two-photon photoreactive properties[78]. Achieving efficient reaction at longer wavelengths is 
difficult due to decreased energy of individual photons at longer wavelengths, and traditionally 
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low extinction coefficients of photolabile compounds at red-shifted wavelengths. Surface 
plasmon resonant nanoparticles with exceptional optical and electronic properties may allow 
more efficient photoreactivity of traditional photolabile compounds due to the concentration of 
the electromagnetic field (i.e. light) in the vicinity of the particle surface (Figure 1-5) [79]. 
Figure 1-5 shows the field lines, excluding those scattered, surrounding a small (x > 1) metallic 
sphere with a size parameter (x) of 0.3, where the particle circumference divided by the 
wavelength of incident light (2πa/λ). The corresponding size parameter of a 50nm diameter 
silver particle irradiated with light at 400nm would be approximately 0.4. 
 
Figure 1-5 – Electromagnetic field lines around a small metallic sphere illuminated by light in 
the UV/Visible range. Dashed vertical line indicates the effective size of the sphere for 
absorption of incident light[79]. 
 
A limited number of reports have been published of photo-responsive metal nanoparticles 
for drug delivery, attributable to the belief that a small metal core may strongly deactivate 
excited states of photoactive units close to the plasmon resonant surface[75]. However, 
preservation or metal-enhancement of photochemistry at the nanoscale, for properly designed 
25 
 
metal nanoparticle systems, has been both predicted[36] and reported[40, 60, 80]. Conditions 
including particle composition, particle size, distance between plasmon resonant surface and 
photo-responsive group, and other properties of photoactive unit itself, need to be precisely 
designed and controlled to allow surface-enhanced photochemistry vs. competitive 
quenching[41]. Hu et al[40], with their work on gold clusters, reported that „it is possible to 
generate sufficiently long-lived excited states in SAMs (self-assembled monolayers on colloidal 
metal) functionalized with photoreactive moieties that effective photochemical modification of 
the metal-dielectric interface can be observed.‟ Nitrobenzyl derivatives on nano-gold surfaces 
have been shown to exhibit similar photoreactivity to that observed in solution phase[17], and o-
nitrobenzyl groups on gold have been used as a means to effect photo-release of electrostatically 
complexed nucleic acids[60]. While most studies of photo-responsive nanoparticles have 
centered around gold-based materials, silver nanoparticles offer higher extinction coefficients 
and blue-shifted plasmon resonant peaks which make them a most appropriate alternative to gold 
nanomaterials for surface-enhanced photochemistry and photo-controlled drug delivery. The 
studies undertaken herein will seek to explore the photochemical properties of oligonucleotide-
loaded photo-responsive silver nanoparticles.  
1.5.2 Photocleavage Reaction Scheme 
 Reviews of currently available photolabile ligands have been published[81], which may 
allow selection of a compound most appropriate for a specific caging application. A caging 
compound will ideally possess high extinction coefficient and quantum yield properties at 
wavelengths which are not detrimental to biological systems. The quantum yield (𝛟) of a 
photochemical reaction is a measure of the efficiency with which absorbed light (incident 
photons) produces photolysis, where unity indicates 100% efficiency. The absorptivity of a 
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compound at a particular wavelength of incident light, in other words the likelihood that a photon 





Beer‟s Law may be used to find the extinction coefficient of a photochemical compound based 
on absorbance measurements:  
𝑨𝝀 =  𝜺 𝑪 𝒍            4  
Where ε is the extinction coefficient, 𝐶 is the concentration of the absorbing molecule, and 𝑙 is 
the optical pathlength. Extinction coefficient known, a functional quantum yield may be 
calculated experimentally for a photochemical reaction: 
𝝓 =  
𝟏
𝑰 𝜺 𝒕𝟗𝟎%
 [82-83]         5 
Where 𝜀 is the decadic extinction coefficient in cm2/mol (or 103 x M-1 cm-1),  𝐼 is the irradiation 




), and 𝑡90% is the irradiation time (in seconds) for 90% 
conversion of the photocleavable compound. 
While many photocleavable compounds exist for caging of biomolecules, 2-nitrobenzyl 
derivatives are some of the most widely used[69]. A 2-nitrobenzyl protecting group was used in 
the first caging of adenosine 5‟-triphosphate (ATP) by Kaplan et al[84], with a reported 
maximum quantum yield of 0.63. 1-(2-nitrophenyl)ethyl phosphate esters have been reported to 
demonstrate high quantum yields (0.49-0.63) in applications of caged nucleotides[85-86]. A 1-
(2-nitrophenyl)ethyl (NPE)-based photocleavable (PC) linker available commercially through 
Glen Research (Sterling, VA) and IDT (Integrated DNA Technologies, Coralville, IA) has been 
used for immobilization onto solid surfaces, purification, and characterization of nucleic 
acids[87]. This PC linker demonstrates high photocleavage efficiency under UV-irradiation 
(300-350nm)[88], and has been chosen as the photo-labile group herein for immobilization and 
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release of oligonucleotides from a metal nanoparticle surface. Upon photo-irradiation, the 
phosphodiester bond between the photocleavable group and the phosphate is cleaved, resulting in 
the formation of a 5‟-monophosphate on the released moiety (oligonucleotide)[87]. The 1-(2-
nitrophenyl)ethyl moiety is converted to a 2-nitrosoacetophenone derivative[85, 87]. The general 
photochemical reaction scheme of an o-nitrobenzyl compound is shown in Figure 1-6. 
 
Figure 1-6 - O-Nitrobenzyl photochemistry[81, 89] 
 
1.5.3 Light Sources 
Typical light sources for uncaging emit UV radiation to excite photolysis of 
photocleavable compounds. Flash lamps, lasers, transilluminators, and laser microscopes with 
UV emissions in the range of 300-360nm are often used for uncaging. Lasers with narrow 
excitations lines or broad bandwidth light sources equipped with filters to select for desired UV-
range wavelengths are appropriate sources. Two-photon excitation sources are also of recent 
interest, where long wavelength light sources replace UV-light sources, and the virtually 
simultaneous absorption of two low energy photons[69] vs. one high energy photon produces 
excitation of the photochemical compound. The electronic properties of SNPs may offer the 
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potential of uncaging at higher wavelengths (visible to IR) due to SPR-enhanced excitation[90], 
which is of interest due to increased tissue penetration of longer wavelength light, and decreased 
probability of damage to biological components caused by high frequency (ultraviolet) 
electromagnetic energy.       
1.6 Antisense Technology and Therapy 
Antisense technology is the subject of much interest in the field of gene therapy, as a 
means to study gene function and to effect gene knockdown in the treatment of genetic disorders, 
cancers, and viral infections[91]. Antisense therapy functions on the basis of nucleic-acid based 
molecules whose sequence can be tailored to target the knockdown of specific gene products. 
This technology has been used control viral gene products and gene products associated with 
various cancers and autoimmune diseases, including notably Crohn‟s Disease[92] for which the 
surface protein product  ICAM1 is targeted by the antisense drug ISIS 2302 (ISIS 
Pharmaceuticals). Antisense „drugs‟ consist of ssDNA, dsDNA, or RNA molecules which work 
at the mRNA or genomic level, preventing splicing, transcription, or translation, via steric 
hindrance or actual degradation of the targeted nucleic acid substrate.  Antisense molecules take 
on several forms, including antisense DNA/RNA oligonucleotides, ribozymes, and small 
interfering RNAs (siRNAs), the latter being the most newly discovered form of antisense which 
is naturally found in many higher organisms.  
1.6.1 Mode of Action 
The concept underlying antisense technology is Watson-Crick base pairing[93] between a 
delivered nucleic-acid based molecule and its complementary intracellular target. By hybridizing 
to a complementary target, antisense oligonucleotides (DNA or RNA) or small interfering RNAs 
(siRNAs) inhibit either transcription or translation, and thus production of a specific protein 
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product. Antisense oligonucleotides function in one of two primary pathways: 1) enzymatic 
degradation of target mRNAs via RNase H 2) steric hindrance of translation, transcription, or 
splicing. Regardless of the mode of action, the end result of antisense therapy is the inhibition of 
a protein product encoded by the affected target nucleic acid. The RNase H pathway has been 
considered a gold standard in antisense technology, due to the fact that the antisense 
oligonucleotides involved are left intact and functional following target mRNA degradation, and 
are thus able to effect the degradation of many target mRNAs[94]. The lifetime of the antisense 
oligonucleotide in this case is the primary limitation of therapeutic effectiveness. Non-specific 
side effects of the therapeutic molecule as well as its intracellular localization may also limit the 
effectiveness of any particular antisense oligonucleotide once delivered to a cellular target.  
RNase H is a ubiquitous enzyme, located in the cellular cytoplasm as well as in the 
nucleus, and is specific for RNA/DNA duplexes. Modifications on the sugar moieties of 
antisense oligonucleotides typically inhibit the action of RNase H[91], and the phosphorothioate 
oligo, in which a sulfur replaces the non-bridging oxygen of the phosphate backbone, is one of 
the few chemically modified antisense molecules which will still activate the RNase H pathway. 
However, even phosphorothioates have disadvantages compared to other antisense oligos, 
including non-specific interactions with proteins and decreased binding affinity for 
complementary nucleic acids when compared to traditional phosphodiester oligonucleotides. 
Studies have also been conducted showing attachment of phosphorothioate modified 
oligonucleotides to metal (gold) nanoparticles in studies on particle-particle linear 
connection/aggregation[95]. Alternative antisense oligonucleotides have been devised which 
bind tightly and specifically to target substrates, and which do not non-specifically bind to 
proteins or other macromolecules[93]. These „second generation‟ oligonucleotides typically 
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function via inhibition of transcription or translation machinery once they are hybridized to 
target DNA or mRNA substrates. 
1.6.2 Antisense Oligonucleotides 
Antisense oligonucleotides are short nucleic acids (10-30 base pairs long)[91] which 
interact with complementary mRNAs or duplex DNAs within the nucleus to prevent production 
of a specific protein product. This inhibition of protein product production at the transcription, 
splicing, or translation level is the hallmark of antisense technology, which may be contrasted to 
the activity of other drugs which may prevent the function of proteins or other biomolecule 
targets already present at the time of drug delivery. Antisense oligonucleotides prevent 
transcription or translation of substrate nucleic acids in a sequence-specific manner, and are often 
directed to the 5‟ initiation sequences or 5‟ UTRs (untranslated regions) when the mode of action 
is steric hindrance[65], or almost any available binding site on an mRNA when the mode of 
action is degradation. It is interesting to note that initiation sequences and UTRs are often 
available for binding due to the fact that these sites are generally accessible to proteins such as 
transcription factors and ribosomes[65].  
 A major problem with traditional (phosphodiester) antisense oligos is their susceptibility 
to degradation in the physiological environment[96]. The half-life of phosphodiester oligos, i.e. 
the time before half the molecules are inactivated by degradation, is only on the order of minutes 
when suspended in serum, or blood plasma. Serum contains 3‟5‟ exonuclease proteins, which 
are the primary agents of degradation for traditional, i.e. phosphodiester, antisense oligos[97]. 
Endonuclease enzymes are also responsible, to a somewhat lesser extent, for oligonucleotide 
degradation in the intracellular environment. Thus, normal phosphodiester oligos have very 
limited use in antisense therapy, and have been replaced with chemically modified 
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oligonucleotides[93] (Figure 1-7) which resist degradation in a physiological environment. An 
important alternative to further chemical modifications of antisense oligonucleotides in 
expanding the utility and impact of antisense technology is the use of novel delivery routes[98] 
and drug carriers which may enhance function and  prevent/delay the enzymatic degradation of 
associated nucleic acids. Significant effort is being dedicated to the discovery and synthesis of 
novel nanoparticulate carriers[65, 99] that will both protect and efficiently „shuttle‟ drugs such as 
antisense oligonucleotides into cells[100]. Enhancement of antisense delivery and targeted 
release based on nanoparticle carriers is a primary subject of the studies herein.  
 The criteria of an „efficient‟ antisense oligonucleotide (or AS-ODN) have been 
enumerated as follows[91]: sequence-specific target recognition, high affinity for target DNA or 
RNA substrates, resistance to nuclease activity, sufficient plasma half-life, minimal „off-target‟ 
or non-sequence-specific effects, and in ideal cases activation of RNase H, which effects 
degradation of target RNAs. There have been many developments in antisense oligonucleotide 
chemistry, and many chemically modified oligonucleotides are now available which have longer 
half-lives in serum and resist nuclease degradation within the intracellular development. 
Phosphorothioate oligos, which have a modified phosphate backbone wherein a sulfur replaces 
the non-bridging oxygen, have a half-life in serum on the order of hours[100]. Phosphorothioate 
oligos, which are among the most extensively studied and practically applied antisense 
oligonucleotides[98], prevent mRNA translation via the RNase H degradation pathway. The use 
of this pathway for degradation of target nucleic acids, as well as the enhanced stability of 
phosphorothioates, creates the appeal of this particular antisense molecule. Other chemically 
altered oligonucleotides with modifications to the phosphate backbone, sugar moieties, or 
nucleotide bases [93, 98] have been employed to minimize degradation or off-target effects of 
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antisense drugs while preserving their specific hybridization to target DNAs/RNAs. Most of 
these modifications[98] produce antisense molecules which function via steric inhibition of 
translation, splicing, or transcription of target nucleic acids.  Antisense RNAs have also been 
chemically modified, via replacement of the ribose sugar 2‟ oxygen with a 2‟ O-methyl  group or 








RNA interference, or RNAi, is an emerging technology which involves the delivery of 
double-stranded siRNAs (small interfering RNAs) which activate intrinsic pathways leading to 
the enzymatic degradation of targeted (complementary) mRNAs[96, 101]. These pathways 
traditionally involve the enzyme complexes known as DICER and RISC, the latter of which 
functions in the unwinding of small double-stranded RNAs and in the cleavage of 
complementary RNAs[91]. RNAi, which is mediated by ssRNAs or small dsRNAs delivered to 
targeted cells, is related to endogenous microRNA pathways[91], which serve to naturally 
regulate gene expression in higher organisms including humans. Although extensive research is 
being conducted in the therapeutic utility of siRNAs, antisense oligonucleotides remain a 
primary tool for gene therapy due to greater flexibilities in the chemistry of these compounds, 
lower synthesis costs, high stability in most cases, and ease of handling and intracellular 
delivery[96].  
1.7 Antisense Macromolecule Intracellular Delivery 
The effective delivery of antisense oligonucleotides to the intracellular environment is an 
essential facet of antisense gene therapy. An effective delivery agent will ideally provide targeted 
(cell-, tissue-, organ-specific) delivery, enhance intracellular penetration, protect the antisense 
molecule from degradation, and prevent entrapment in endosomal/lysosomal compartments, 
while remaining minimally cytotoxic[100]. A further ideal in antisense delivery is specific 
targeting of therapeutics to particular tissues/cell types, as well as spatiotemporally controlled 
activation („uncaging‟) or release from delivery vehicles[99]. „Drug-flooding‟ is no longer a 
valid method of achieving therapeutic concentrations of drugs at target locations[68], thus we see 
increased importance of designing „smart‟ delivery systems[68] for the more safe and efficient 
34 
 
delivery of antisense therapeutics. The manipulation of antisense oligonucleotides via chemical 
modifications may reach functional limitations, at which point vehicles for enhanced delivery, 
biodistribution, and controlled function of these therapeutics gain considerable interest in 
antisense technology. The limitations of antisense drugs which may be overcome by novel 
delivery vehicles include low permeability of the plasma membrane to naked oligonucleotides, 
difficulty of attaining therapeutic concentrations in target cells/tissues, and the tendency of 
foreign nucleic acids to be sequestered and degraded in endosomal/lysosomal intracellular 
compartments[100].  
1.7.1 Overview of Delivery Methods 
An entire field of research has been devoted to the development of methods for gene 
delivery to and transfection of cellular targets for the purpose of gene therapy. These methods 
may typically be classified according to their delivery approach: mechanical, electrical 
(electroporation), and/or chemical[102]. Many non-viral chemical approaches for nucleic acid 
delivery have been and continue to be the subject of extensive research. The efficacy of virus-
mediated delivery has been a functional ideal in gene therapy, due to the natural ability of virus 
particles to traverse the cell membrane and efficiently insert their genome into host cells. 
However, due to the safety issues associated with use of viral carriers, non-viral carriers are a 
more viable option for enhanced antisense drug delivery. The intrinsically low permeability of 
the cell membrane to negatively charged nucleic acids has been surmounted by the use of 
cationic biomolecules, including synthetic lipids, polymers, proteins, and dendrimers, as non-
viral delivery agents [63, 65, 103-104].  Cationic lipids and polymers are typically recognized as 
some of the most successful chemical delivery agents of therapeutic nucleic acids to date[63, 98]. 
The polar heads of cationic lipids interact electrostatically with DNA, and complex with the 
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DNA to form liposomes which can naturally cross the hydrophobic lipid bilayer of the cell 
membrane[67]. Cholesterol and „helper lipids‟ such as DOPE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine) can aid membrane fusion[104] of the lipoplexes and enhance intracellular 
trafficking, respectively. Cationic polymers have also been successful in the efficient delivery of 
electrostatically complexed antisense nucleic acids. High buffering-capacity polymers, notably 
the cationic polymer PEI (polyethylenimine), have been used in order to help charge-associated 
oligonucleotides to escape from endosomal compartments via the proton sponge effect [105-
106]; in essence the buffering capacity of PEI causes continual pumping of ions into the early 
lysosomal compartment, to the point at which the vesicle ruptures due to osmotic pressure, 
releasing the in-dwelling antisense molecules. PEI has been combined with other delivery 
vehicles [66, 106] in order to increase their effectiveness in the delivery of antisense molecules 
to the cytoplasm of target cells.  
Although lipid and polymer transfection agents by themselves can be useful in loading 
large amounts of DNA into subject cells, they still suffer from limitations, including limited 
controllability, limited conferred stability onto electrostatically complexed nucleic acids, and a 
level of toxicity in most cases[50]. An exciting potential in drug delivery systems arises not from 
the use of these transfection components alone, but from the possibility of integrating these 
components with novel nanoparticles carriers to enhance cell delivery add create controllable and 
specifically targeted drug delivery vehicles. Lipid and polymer nanohybrid systems have 




1.7.2 Nanoparticle Delivery of Antisense Drugs 
Metallic nanoparticles offer the potential advantages of their electronic and optical 
properties along with the highest standards of antisense drug delivery vehicles. The advantages 
of metallic nanoparticles as delivery vehicles for antisense oligonucleotides include ease of 
nanoparticle synthesis, tailorable size and morphology properties, ease of surface ligand 
functionalization, presence of a solid surface for high density loading, enhanced stability and 
lifetime of bound nucleic acids[5], enhanced cellular uptake[11] with high loading densities, and 
potential of surface-enhanced fluorescence (detection) and photochemical processes. Metallic 
nanoparticles, almost exclusively gold nanomaterials, have been employed as novel antisense 
therapeutic vehicles when functionalized with antisense DNA[4, 11, 13] or siRNA[12, 108-110]. 
According to a recent review article in Science, the three biggest problems with RNAi 
therapeutics remains “delivery, delivery, delivery.”[111] While lipid and polymer-based particles 
and nanostructure carriers are currently the most widely used and viable delivery agents for 
antisense therapeutics, metallic nanoparticles provide the efficient delivery offered by these, 
while further providing ease of fabrication of multicomponent systems and enhanced control 
over intracellular release. Metallic nanoparticles may be functionalized with mixed monolayers 
for the further tailoring and enhancement of uptake, delivery, and release of antisense 
therapeutics. PEGylated siRNA gold nanoparticles have been reported with enhanced cell uptake 
and pronounced RNAi activity[108].  Novel multicomponent nanoparticulate systems for 
antisense delivery have been devised which incorporate uptake-enhancing and endosome-
escaping polymers with metal nanoparticles serving as solid support delivery systems for nucleic 
acids [66, 110]. 
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1.7.3 Silver Nanoparticles: Nontoxic Delivery Vehicles 
 In order for silver nanoparticles to be used in therapeutic delivery applications, the effects 
of SNPs on cell health must be studied, and shown to have no adverse affects at therapeutically 
applicable concentrations. The focus of nanosilver materials in medicine has been on their 
multilevel anti-microbial activity[112], with applications in wound treatment/healing[112-113], 
nanosilver-based dressings, surgical sutures, and surgical implants. Recently, studies on the use 
of SNPs in therapeutic applications, for example drug delivery, have met with concerns about the 
toxicity and negative effects of silver nanomaterials. 
Concerns of the impact of silver nanoparticles on cell health include decrease of 
mitochondrial function and induction of apoptosis, the mitochondria being a sensitive target of 
cytotoxicity of SNPs[114]. While the mechanisms of silver nanoparticle toxicity are not well 
characterized, they may involve surface binding (depletion) of thiol-containing proteins, 
including glutathione and key component enzymes of the cell‟s antioxidant defense mechanism, 
which leads to increased reactive oxygen species (ROS) generation, oxidative damage[114], and 
apoptosis, a complex programmed cell death pathway. Particle surface electrostatic interactions 
with charged biomolecules might also attribute to the toxic properties often observed for „naked‟ 
silver nanoparticles at high concentrations[115]. While the negative effects of SNPs are of 
concern in therapeutic applications, especially the localization of SNPs in the mitochondria and 
generation of oxidative stress, current studies reveal that upon SNP uptake cellular antioxidant 
systems are triggered and their activity increased, preventing extensive oxidative damage[112]. 
Recent studies have also shown that primary cells have much higher SNP tolerance than 
concentrations often used for antimicrobial effectiveness[116]. Efforts to improve the 
biocompatibility of metallic nanoparticles include functionalizing the particles with 
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biocompatible biomolecules, i.e. poly(ethylene)glycol (PEG) groups, lipids, polymers, small 
peptides, etc. The surface modification of silver nanoparticles with thiol-modified biomolecules 
has been shown to improve silver biocompatibility and intracellular uptake[115]. In the cited 
study, phospholipid-protected silver nanoparticles were delivered into 3T3 fibroblast cells and 
platelet cells with minimal toxic effects. Thus silver nanoparticles may hold more potential in 
therapeutic applications than previously considered, and studies for the development on SNP-
based antisense delivery platforms are justified. The effects on non-functionalized vs. nucleic-
acid functionalized SNPs on cell health will be evaluated in studies proposed herein. 
1.8 Model System for Antisense Therapy Evaluation  
Model genetic systems are often useful for the analysis of the applicability of newly 
designed antisense therapeutics. Once a new delivery platform has been designed and 
characterized in vitro, analysis of performance must be carried out in the context of a living 
biological system, ex vivo/in vivo. Model systems may consist of transgenic cell lines induced to 
express specific protein products or markers, for example GFP (green fluorescent protein)[13], in 
high quantities for ease of antisense activity analysis of delivered therapeutics. Gene expression 
and silencing may be monitored by use of a model system when can be induced at a specific 
point in time, even after drug delivery, to begin expressing a targeted gene product.  
The model system which will we will use is based upon the expression and production of 
intracellular adhesion molecule-1 (ICAM-1), a cell-surface transmembrane glycoprotein 
constitutively expressed by leukocytes and endothelial cells[117]. ICAM-1(CD54) mRNA 
expression and protein production can be upregulated in a dose-dependent manner by 
inflammatory mediators such as the cytokine interferon gamma (INF-γ)[117-118]. The ICAM-1 
protein can easily detected by anti-human CD54 fluorophore-labeled monoclonal antibody, a 
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detection mechanism which serves as a validation of the expression level and knockdown 
activity of antisense oligonucleotides specific for ICAM mRNA. This makes ICAM upregulation 
as a molecular method for antisense activity analysis especially attractive, as live-cell surface 
protein antibody labeling is a valid indication of gene expression levels. A well known antisense 
oligonucleotide targeting the ICAM-1 mRNA (ISIS 2302, ISIS Pharmaceuticals Inc., Carlsbad, 
CA), developed for the treatment of Crohn‟s Disease[98], will be employed to investigate the 
activity of caged/uncaged SNP-antisense conjugates in our ex vivo studies. 
1.9 Significance 
 Targeted delivery and controlled release of therapeutics in vivo, including antisense 
nucleic acids, are important goals of modern biotechnology and medicine[2]. Biomolecule 
functionalized metal nanoparticles with photo-responsive moieties[68] hold much potential as 
stable drug carriers with unique optical and photo-activated properties. Silver, as one of best 
surface-enhancing substrates, is a prime choice for studies on the potential of metal nanohybrids 
as novel „caging‟ compounds with metal-enhanced photo-release of cargo therapeutics.   
Studies focusing on the advancement of delivery agents and targeting/release methods 
have risen to the top of the list of goals in nanomedicine and antisense technology[16]. While 
antisense therapeutics, as drugs which can be tailored to target any gene or gene regulator for 
which we know the sequence, are potential „superdrugs‟ for gene therapy, novel delivery 
technologies are required to enhance their efficacy, increase their physiological stability, and 
minimize side effects in vivo[91]. Cell uptake and intracellular trafficking of delivered 
therapeutics, such as antisense molecules, is a complex process, and may require 
multicomponent systems with diverse functions for optimal delivery. Tekmira Pharmaceuticals‟ 
SNALP (stable nucleic acid-lipid particle) technology, which has been used in Phase 1 clinical 
40 
 
trials, incorporates “four distinct lipids, which play distinct roles in the pharmacokinetics and 
pharmacodynamics of the product.”[111] Metal nanoparticles functionalized with biomolecules 
are prime targets for the development of multicomponent systems, incorporating diverse levels 
of function within the physiological environment. Metal nanoparticles provide a solid support for 
attachment of both the cargo therapeutic and delivery-enhancing agents (lipids, polymers, 
peptides, etc.), unique electronic and optical properties with applicability to enhanced 
spatiotemporally controlled release and activation, tailorable surface distribution of ligands for 
either enhanced or decreased (caged compounds) availability of surface-bound therapeutics for 
binding to physiological targets, and many other novel delivery properties. 
To date, most nanoparticle-based drug delivery has taken advantage of relatively inert 
gold nanoparticles and other noble metal nanomaterials, with the exception of silver. This is due 
to the difficultly of silver synthesis and functionalization compared to that of gold, lesser 
stability when functionalized according to popular salt-aging techniques, and concerns about 
silver toxicity.  However, recent improvements in silver nanoparticle biocompatibility via 
surface modification and the exceptional optical and surface-enhancement properties of silver 
nanoparticles has lead to interest in developing an SNP-based antisense drug delivery platform 
for photo-activated gene silencing, which is the subject of the herein proposed studies. 
1.10 Potential Difficulties and Alternative Methods 
Difficulties which have been and may still be encountered in this project are diverse, 
including maintaining colloid stability during functionalization and purification, obtaining 
photorelease of particle-bound oligonucleotides while preventing false-negative results due to 
non-specific oligonucleotide interactions with the metal surface, and both foreseen and 
unforeseen difficulties with achieving efficient cell uptake with no adverse effects on cell health, 
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diffuse intracellular distribution, and detection of SNP-oligonucleotide conjugate release 
properties in vivo. 
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Chapter 2. Silver Nanoscale Antisense Drug Delivery System for 
Photoactivated Gene Silencing 
 
2.1 Introduction  
Targeted delivery and controlled release of antisense therapeutics in vivo are essential 
aspects of an „ideal‟ delivery vehicle[100]. In this study we have undertaken the synthesis and in 
vitro/intracellular characterization of silver nanoparticle (SNP) photolabile nucleic acid 
conjugates, with the aim of developing a silver nanoparticle-based platform for therapeutic 
oligonucleotide delivery and photo-activated gene silencing. Nanostructures, which are amenable 
to molecular detection, intracellular diagnostics, and drug delivery applications due to their sub-
microscopic dimensions (<1 um) and the unique electronic and photonic properties which 
emerge at these dimensions, have emerged been increasingly utilized within the last decade[1]. 
The vast majority of nanoscale delivery platforms to date are polymeric in makeup. However, a 
focus on metallic nanoparticles offer benefits for drug delivery applications due to their tunable 
size, shape, and functionality attributes; relative ease of bulk synthesis via „wet chemistry‟ 
techniques[2]; large surface area-to-volume ratio; simple covalent coupling chemistries to 
metallic surfaces [3-4], enhanced stability of surface-bound macromolecules including nucleic 
acids[4-5], and the exploitation of unique intrinsic photophysical properties of small noble metal 
particles[17]. Here the photophysical properties of silver nanoparticles are harnessed for both 
enhanced detection and spatiotemporal control over release of surface-bound therapeutics. 
Antisense therapeutics, powerful nucleic acid drugs tailored to target any gene product 
for which the genomic, mRNA, or regulation sequence is known, are potential „superdrugs‟ for 
gene therapy[91]. However, improved delivery technologies are required to enhance their 
efficacy, increase their physiological stability, and minimize side effects in living systems. Cell 
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uptake and intracellular trafficking of delivered antisense therapeutics is a complex process, and 
may require multicomponent systems with diverse functions for optimal delivery. Antisense-
nanoparticle composites are prime targets for the development of multicomponent systems, 
incorporating diverse levels of function within a single drug delivery platform.  
Here we report the synthesis of UV-photo-activated silver nano-carriers of antisense 
therapeutics which, when compared to traditional solution-phase nucleic acids, exhibit enhanced 
stability, decreased susceptibility to enzymatic degradation, enhanced cellular uptake, and 
enhanced cellular distribution and activity upon photo-release. To date, most nanoparticle-based 
drug delivery has utilized relatively inert gold[11-13] and other metallic and non-metallic 
nanomaterials[50, 119]. Silver has not been applied in such applications, likely due to the 
difficultly of silver synthesis and functionalization compared to that of gold, lesser stability when 
functionalized according to popular salt-aging techniques, and concerns about silver toxicity. 
However, recent improvements in silver nanoparticle biocompatibility via surface modification, 
as well as the exceptional optical[22, 42] and localized surface plasmon resonance (LSPR) 
enhancement[29] properties of silver nanomaterials have lead to its suitability for this 
application. Localized surface plasmons (LSPs), excitations of the conduction-band electrons of 
sub-wavelength conductive nanoparticles[18], create a condensing effect of incident light at 
particle surfaces, which in turn produces large local enhancements of E-fields. These 
enhancements form the basis of surface-enhanced spectroscopy and photochemistry 
techniques[9]. The unique light-scattering and field-enhancement properties of silver 
nanoparticles, where the scattering cross section of a silver particle is about 10 times greater than 
that of a gold particle of the same size[22], have led to increased interest in their use as 
sensors[34, 49], biological labels[22], and substrates for surface-enhanced absorption, 
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fluorescence[120], and photochemistry[17, 121]. Our SNP-based platform for antisense drug 
delivery takes advantage of the unique photo-physical properties of silver nanoparticles for 
fluorescence confirmation of surface functionalization, cell uptake, and light-triggered activation 
of therapeutic SNP-oligo conjugates. 
2.2 Experimental Approach 
The fabrication of silver nanoparticle (SNP)-based antisense drug delivery vehicles was 
initiated with synthesis of raw SNP substrates and functionalization of substrate surfaces with 
oligonucleotide ligands, and completed with full solution and in vitro cell culture 
characterization of oligonucleotide nanocomposites. A citrate-reduction SNP synthesis method 
was chosen due to ease of bulk synthesis within the desired 40-80nm diameter size range and 
simple replacement of the citrate capping moiety (citrate) with thiol-modified nucleic acids. A 
Tris-buffer based salt-aging process[56] was used adapted from a Lee and Meisel method to 
develop stable SNP-conjugates functionalized with fluorophore-labeled thiol end-modified DNA 
oligonucleotides. These oligonucleotides were synthesized with an internal nitrobenzyl 
photocleavable linker (IDT, Coralville, IA) which when exposed to UV-wavelength light, 
initiates disengagement of a functional oligonucleotide from the protected nanohybrid surface. 
 Physiochemical confirmation of the synthesized SNP-oligonucleotide conjugates was 
accomplished via UV-Visible spectroscopy, transmission electron microscopy (TEM), and 
fluorescence-based surface coverage analysis techniques. These techniques served to 
characterize and quantify ligand attachment, stability, and surface properties of the SNP-
oligonucleotide conjugates. Functional properties of the SNP-oligo conjugates were assessed via 
hybridization and nuclease digestion assays, the goal of these studies being to prove enhanced 
stability and reduced availability of particle-immobilized oligonucleotides for hybridization prior 
53 
 
to photo-activation. Photoreactivity of SNP-bound oligonucleotides possessing internal 
photocleavable (PC) nitrobenzyl linkers were characterized and in future work will be compared 
to that of identical oligonucleotides in solution (non-immobilized) via fluorescence-based 
analyses and HPLC.  
 Cell culture studies were utilized for confirmation of SNP-oligo conjugate intracellular 
delivery, ligand photo-release, sub-cellular localization, and photo-activated antisense activity, 
which were assayed via time-lapse fluorescent confocal imaging and TEM. The antisense 
activity of developed SNP-oligo conjugates was demonstrated via ICAM1 (Intracellular 
Adhesion Molecule-1) protein expression knockdown in HeLa cells.  
2.3 Study Objectives and Work Plan 
The approaches for our work are classified into the following experimental objectives: 
silver nanoparticle (SNP) synthesis and characterization; SNP conjugate synthesis via surface 
functionalization techniques; In solution qualitative, quantitative, and functional characterization 
of SNP conjugates; evaluation of SNP conjugate photochemistry; and finally in vitro cell culture 
studies of SNP conjugates as photo-activated antisense drug delivery vectors. We will utilize 
primarily optical-based techniques to accomplish our objectives, including TEM, absorbance and 
fluorescence spectroscopy, and confocal microscopy. 
2.3.1 Reagents 
2.3.1.1 SNP Synthesis and Functionalization 
Silver nitrate (SigmaUltra >99%) and sodium citrate were purchased from Sigma Aldrich 
(St. Louis, MO). Other materials for SNP synthesis included PTFE coated stir-bars (VWR, West 
Chester, PA), 100ml glass syringes (KD scientific, Holliston, MA), and SNP synthesis-reserved 
glassware (Fisher Scientific, Pittsburgh, PA). Silver surfaces were functionalized with custom 
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thiol-modified oligonucleotides ordered from Integrated DNA Technologies (IDT, Coralville, 
IA). 2M Tris-NaCl buffer (pH 8.0) was made up from Biotechnology grade Tris (Amresco Inc, 
Solon, OH) and sodium chloride (Fischer Scientific, Pittsburgh, PA). Dithiothreitol (1M 
aqueous) purchased from Sigma (St. Louis, MO) was employed for DTT-mediated 
oligonucleotide removal from SNP surfaces.  
2.3.2 Methods 
The following flow chart is a representation of the methods employed in synthesis and 
full characterization of SNP-oligo conjugates: 
 
Figure 2-1 – Flow diagram of experimental objectives and work plan 
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2.3.2.1 SNP Synthesis 
Citrate-reduced silver colloid was prepared according to a modified Lee and Meisel 
method[43]. Silver nitrate (90mg) was suspended in distilled water (500mL), and heated rapidly 
to boiling (95-100°C) under continuous stirring. Upon boiling, a 1.0% solution of sodium citrate 
(10mL) was added dropwise with a syringe-pump automated flow-rate (0.5 mL/min), while 
solution color progression from pale yellow to dark green signified formation of silver colloid.  
The solution was allowed to boil for the duration of citrate addition plus 10 minutes following 
addition, to ensure complete reduction of silver nitrate. The colloid was allowed to cool to room 
temperature prior to characterization via visible absorption spectroscopy and transmission 
electron microscopy (TEM).  
 
Figure 2-2 Schematic of Fluor-Oligo functionalized silver nanoparticle 
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2.3.2.2 Design of SNP-conjugate Oligonucleotides 
The photo-labile oligonucleotides for conjugation  to SNP surfaces were designed in such 
a manner as to optimize surface coverage, SNP-conjugate stability, and surface-enhancement of 
photochemical processes, including fluorescence detection and photolysis of the nitrophenylethyl 
(NPE) internal photocleavable linker (Figure 2-2). A 10mer thymine linker was incorporated into 
the 3‟thiol-modified oligonucleotides in order to enhance particle surface coverage, due to the 
fact that thymine has been previously shown to have the least affinity for metal surfaces of the 
four available nucleotides[48], thus reducing non-specific oligo-metal interactions. Spacer thiols 
have also been shown to reduce the non-specific adsorption of nucleic acids onto metal particle 
surfaces[52] by competing for surface attachment sites, thus an alkane spacer thiol 
(mercaptopropanol) has been incorporated which adsorbs to the metal surface concurrently with 
the target oligonucleotide (Figure 2-2). 
The particle-bound thiol-modified oligos have as their base the ISIS 2302 sequence, 
which is an established antisense sequence against ICAM-1 (CD54) [98]. This system will serve 
as a proof of concept in studies on SNP-mediated antisense drug delivery and controlled release. 
A simple thiol-modified ISIS 2302 sequence oligonucleotide (1a) was used as a control for 
immobilization of nucleic acid onto silver surfaces and characterization of surface coverage. A 
TYE(563) fluorophore-labeled oligonucleotide (1b) was designed for fluorescence detection  of 
oligonucleotide in solution and attached to SNPs. The excitation/emission (549/563nm) 
properties and particle-fluor spacing (10-12nm based on a 30mer separating oligonucleotide 
sequence) were chosen to minimize overlap with intrinsic SNP fluorescent properties in the SPR 
region and quenching by the silver surface. Of the two oligonucleotides studied for 
photocleavage analysis, the photocleavable group in the TYE-NPE(1n)-oligo (2a) (Figure 2-3) is 
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spaced from the particle surface by a three carbon alkane thiol (ThiolMC3) plus one thymine 
nucleotide, while the photocleavable group in the NPE(10n)-oligo (2b) (Figure 2-3) is spaced 
from the particle by a three carbon alkane thiol plus a thymine linker sequence of 10 nucleotides.  
The thiol linker (3-carbon alkane chain) is estimated to have a linear length <1nm, based on 
reported C-C, C-S, and S-Ag bond lengths[122], and the nitrobenzyl linker an estimated linear 
length slightly greater than 1nm based on traditional bond lengths. Oligonucleotide length is 
estimated based on a .3-.35nm/base unit length[123]. This leads to particle-to-photolabile linker 
distances for the SNP-TYE-NPE(1n)-oligo conjugates and SNP-NPE(10n)-oligo conjugates of 2-
3nm and 5-6nm, respectively. The different particle to photocleavable group spacing distances 
will serve to help evaluate distance-dependent influences of silver surface-plasmon resonance on 
the NPE photochemical reaction. 
 
Figure 2-3 - Design of current oligonucleotides for SNP functionalization. 1a) Thiol-modified 
oligonucleotide 2a) Fluorophore-labeled thiol-modified oligonucleotide with 1-thymine linker 
(TYE-NPE(1n)-oligo). 2b) Non-labeled thiol-modified oligonucleotide with 10-thymine linker 
(NPE(10n)-oligo) 
 
2.3.2.3 SNP Functionalization 
Silver nanoparticles were functionalized via a modified „salt-aging‟ technique. Custom 
thiol-modified TYE563
TM
-labeled oligonucleotides (Integrated DNA Technologies, Inc) were 
mixed with silver colloid (50pM) at a oligo-to-particle stoichiometry of 5000:1, and left to 
incubate at 37°C under gentle rocking conditions to favor initial oligonucleotide. Following a 
24hr incubation period, a 48hr Tris-buffer based salt-aging process was commenced during 
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which the SNP-oligo conjugate solution was first rapidly adjusted to 1% SDS and 25mM 
phosphate buffer, and subsequently slowly (4x 10ul aliquot additions of a 1M Tris-NaCl buffer 
per 24hrs) adjusted to 80mM NaCl and 80mM Tris buffer (pH 8.0) concentration. Functionalized 
nanoparticles were purified via centrifugation (3 x 7000 RPM) and resuspended in a modified 
buffer (1% SDS, 50mM Tris-NaCl) prior to experimental analysis.     
2.3.2.4 Naked and Functionalized SNP Characterization 
For UV-Visible and fluorescence spectroscopic characterization, naked and 
oligonucleotide functionalized SNPs were diluted to appropriate concentrations in DI water. 
Diluted samples were analyzed for absorption properties in a wavelength range scan (200-
700nm), and for single excitation (420nm and 520nm), multiple emission fluorescence properties 
using a PE LSB-50 spectrofluorimeter. Spectra were normalized to maximum SPR absorption 
and particle fluorescence conditions. 
For TEM characterization, 5 ul of SNP solution and 5ul of SNP-Thiol-oligo(1a) 
conjugate solution were pipetted on Carbon/Copper 20-30 nm grids (EMS, Hatfield, PA), air 
dried and visualized with JEOL 100CX. MetaVue image analysis (Universal Imaging 
Corporation, West Chester, PA) was employed to determine particle counts and average particle 
size from TEM images.  
2.3.2.5 DNA Coverage Quantification  
 DNA coverage on functionalized SNP-conjugates was quantified via fluorescence-based 
measurements and confirmed via gel electrophoresis of particle-released oligonucleotide 
samples. Following SNP-conjugate functionalization and purification via centrifugation (3x 
7000RPM), 1% dithiothreitol (DTT) was added to SNP-conjugate solutions and allowed to shake 
at 37 °C for 10-15min. Following an additional purification step to remove DTT-released 
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oligonucleotide from silver colloid (1x 7000RPM), released oligonucleotide-supernatant was 
analyzed via fluorimetry with excitation/emission lines set at 549/563nm (TYE-fluorescence 
spectra, Integrated DNA Technologies, Coralville, IA) on a PE LSB-50 spectrofluorimeter. A 
TYE-oligo fluorescence calibration curve was used to indirectly quantify TYE-oligo coverage on 
SNP surfaces based on solution measurements (supplemental information Figure 2-14).  
2.3.2.6 In Vitro Hybridization Activity 
 Hybridization activity studies were carried out following SNP functionalization and 
conjugate purification. A FAM-BHQ molecular beacon with a sequence complementary to the 
ISIS 2302 sequence of the oligonucleotide ligands was hybridized to both SNP-bound and SNP-
released oligonucleotide samples.  Hybridization conditions were 30min at 60 °C followed by 
15min at 4°C. These conditions were chosen based on a TM of 40.7 °C for the highest energy 
hairpin folding structure of the molecular beacon (IDT SciTools mFold, Coralville, IA). 
Releasing conditions included both UV-light exposure and 1% DTT treatment. Oligonucleotide 
and oligonucleotide-beacon duplex samples were purified and removed from silver nanoparticle 
surfaces prior to fluorescence analysis via fluorimetry with excitation/emission lines set at 
549/563nm for TYE-fluorescence and 480/520nm for FAM-fluorescence. For SNP-bound 
samples, FAM-BHQ molecular beacon was added to 500ul of SNP-oligo conjugates at a final 
concentration of 0.6uM (.3 nmoles). Following hybridization, free molecular beacon was 
removed via centrifugation (1x 7000RPM), and oligonucleotide and duplex ligands were 
removed from particle surfaces via DTT treatment (1x 7000RPM) for fluorescence and gel 
analysis. For SNP-released samples, oligonucleotide was removed via DTT after which FAM-
BHQ molecular beacon was added, hybridized, and purified from SNP surfaces (1x 7000RPM) 
similar to above. Fluorescence and gel analysis provided comparison of ssDNA vs. DNA-beacon 
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duplex in both SNP-bound and SNP-released cases. A solution hybridization control was run via 
gel electrophoresis (.15 nmoles FAM-BHQ molecular beacon, .05 nmoles TYE-oligo) to confirm 
gel results of experimental samples. All samples were desalted via spin columns (3kDa Amicon 
Ultra filters, Millipore, Billerica, MA) and dried via vacuum centrifuge to a final volume of 
<10ul for final gel preparation. Samples were analyzed via UV-gel electrophoresis and Sybr 
Green staining (Invitrogen Corporation, Carlsbad, CA). 
 
Figure 2-4 - Hybridization assay schematic. A) Quantification of hybridization of molecular 
beacon (MB) to TYE-NPE(1n)-oligo in particle-bound case. B) Quantification of hybridization of 
MB to TYE-oligo in DTT-released and photo-released cases. 
2.3.2.7 In Vitro Protection from Nuclease Activity 
 Protection of SNP-bound oligonucleotides from nuclease activity was investigated via a 
DNase I digestion assay on free solution DNA and surface-bound DNA alike. 1ml of prepared 
SNP-TYE-oligo conjugate was purified via centrifugation (2x 7000RPM) and resuspended in 
500ml of 1x DNase I NEB buffer (New England BioLabs, Ipswich, MA). 1.5ug of free solution 
TYE-labeled oligonucleotide was also suspended in 500ml of 1x DNase I NEB buffer prior to 
DNase I digestion. 4U of DNase I (stock concentration 2U/ml) was added to sample solutions 
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and incubated at 37°C for intervals of 5, 15, and 45min. Following digestion intervals, DNase 
stop buffer (.5M EDTA) was added to each sample to a final concentration of 5mM. SNP-TYE-
oligo conjugates were purified via centrifugation (1x 7000RPM) followed by 1% DTT-mediated 
removal of DNA as described previously. Free solution and particle-bound DNA samples were 
desalted via spin columns (3kDa Amicon Ultra filters, Millipore, Billerica, MA) and dried via 
vacuum centrifuge to a final volume of <10ul. Samples were analyzed via gel electrophoresis 
and fluorescent-gel imaging (Typhoon 8600, GE Healthcare Life Sciences, Piscataway, NJ). 
2.3.2.8 In Vitro Photo-release Efficiency 
Proof of photolabile oligonucleotide release from particle surfaces was demonstrated via 
solution fluorescence and fluorescent gel electrophoresis mediated detection of TYE-labeled 
nucleic acid ligands. 1ml of prepared SNP-fluor oligo conjugates were loaded in a demountable 
quartz cuvette chamber (5mm path length, 49-Q-5, Starna Cells Inc, Atascadero, CA) and 
irradiated at 320nm by means of a UVP-Transilluminator and at 365nm by means of a 
GreenSpot system (American Ultraviolet, Lebanon, IN), which incorporates a 100–watt, 
pressurized mercury lamp with 5mm x 1000mm light guide, and produces a peak spectral output 
at 365nm (American Ultraviolet, Lebanon, IN). The lamp has a fluence of 206 mW/cm
2
 with the 
short bandpass (1.5mm thick, 2.4mm diameter SWP–2502U–400, Lambda Research Optics, CA) 
and IR filters (818–ST–UV detector, Newport Corporation, Irvine, CA) in place. Released 
oligonucleotides were purified via centrifugation (1x 7000RPM) from SNP substrates in order to 
conduct fluorimetry and fluorescent gel electrophoresis (Typhoon 8600, Excitation laser: 532nm, 
Emission filter: 560LP) analysis. Extinction coefficient values for the internal NPE linker were 
calculated according to absorption values found by absorption spectroscopy of TYE-NPE(1n)-
oligonucleotide (2a) with an incorporated NPE photocleavable linker. 
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2.3.2.9 Cell Culture 
HeLa cells (human epithelial carcinoma cells, American Type Culture Collection) were 
maintained in 25 cm
2
 flasks (BD Falcon, Franklin Lakes, NJ) with 5 mL of Dulbecco‟s Modified 
Eagle‟s medium-reduced serum (DMEM-RS, Hyclone Thermo Scientific, Logan, UT) 
supplemented with 3% fetal bovine serum (FBS, Hyclone Thermo Scientific, Logan, UT) and 
incubated at 37 °C in a humidified atmosphere containing 5% CO2. Opti-MEM
®
 (OM, 
Invitrogen Corporation, Carlsbad, CA) is a reduced protein non-phenol-red medium which was 
used for imaging purposes. 
2.3.2.10 Confocal Microscopy Analysis of SNP-conjugate Delivery, Subcellular 
Localization, and Photo-release Profile  
Confocal microscopy was used to monitor SNP-oligo conjugate intracellular delivery, 
trafficking, and photo-release. For imaging purposes, HeLa cells were seeded in 1.0 Borosilicate 
coverglass Lab-Tek™ 8-well chambered slides (Thermo Fisher Scientific, Rochester, NY). Final 
cell media volume in each chamber well was 400ul. Cells were allowed to incubate for 24hrs in 
DMEM+FBS media at 37°C prior to SNP-oligo conjugate treatment. 5ul of 1x naked SNPs and 
5ul of concentrated 5x SNP-oligo conjugates (50pM, ≈1-2ug oligo) were added directly to 
culture 8-wells. Treated cells were incubated at 37°C in a CO2 incubator for 16 hrs following 
addition prior to live confocal imaging. For subcellular localization of SNPs vs. SNP-thiol-oligo 
conjugates, treated cells were stained with LysoTracker (Invitrogen Corporation, Carlsbad, CA) 
for 1hr at 50nm staining concentration. For photo-release profile studies, cells were flashed for 
3min @365nm (18 J/cm
2
) 2hrs prior to imaging (16hrs post SNP-Fluor-oligo conjugate 
delivery). All samples were resuspended in Opti-MEM
®
 prior to imaging. The Leica TCS SP2 
spectral confocal & multiphoton system used consists of a Leica DM IRE2 inverted microscope 
with a galvo-Z stage, equipped with Ar/Kr, He/Ne green, and He/Ne red lasers. Of the provided 
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laser lines, excitation lasers at 488, 543, and 633nm were used in imaging experiments, 
concurrently with tuned emission wavelength windows. Reflectance mode images of silver 
nanoparticles were acquired by centering the emission wavelength directly on the 488nm 
excitation line. Images were analyzed using Leica Confocal Software (LCS) Lite (Leica 
Microsystems Heidelberg GmbH). 
2.3.2.11 Antisense Activity of SNP-oligo Conjugates  
Antisense activity of SNP-oligo conjugates against plasma membrane surface protein 
ICAM1 in HeLa cells was monitored via confocal microscopy. HeLa cells were seeded as 
described above. ICAM1 antisense oligonucleotide transfection was carried out 16hrs prior to 
experimental analysis via TurboFect
TM
 cationic polymer for naked DNA delivery, and SNP-oligo 
conjugates for nanoparticle-bound DNA delivery. TurboFect-oligonucleotide polyplex samples 
were prepared by mixing 1.5ug of TYE-NPE(1n)-oligonucleotide or phosphorothioate ISIS2302 
oligonucleotide with 0.8ul of TurboFect stock reagent in 100ul OM for 15min at room 
temperature and then added directly to culture 8-wells in a 1:5 volumetric ratio. SNP-Fluor oligo 
conjugates were added to culture wells as described previously. ICAM1 was upregulated in 
HeLa cell samples with recombinant human interferon-gamma (INF-γ, 16.9 KDa, eBioscience
®
, 
San Diego CA) by adding 10ug/ml to culture wells 12hrs prior to Anti-human CD54-APC 
(Allophycocyanin) conjugated antibody staining (Mouse monoclonal to ICAM1, AbCam
®
, 
Cambridge, MA) and confocal imaging. Photo-release of antisense ISIS2302 from SNP-
conjugate surfaces was effected by flashing @ 365nm 6hrs post-INF-γ treatment and 6hrs pre-
imaging. Flashing doses were as follows: 15 J/cm
2
 (low flash), and 25 J/cm
2
 (high flash). Cells 
were rinsed with and stained in Opti-MEM
®
 with 2%BSA for 1hr with 10ul CD54-APC 
antibody stock and finally resuspended in Opti-MEM
®
 for imaging purposes. 
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2.4 Results  
2.4.1 SNP Synthesis 
Synthesized silver colloids were characterized via optical techniques including UV-Vis 
spectroscopy and transmission electron microscopy (TEM). Based on TEM images, the average 
particle diameter was calculated to be 60nm±20nm. Particle size is dependent upon the ratio of 
reducing agent to silver nitrate in the sodium-citrate reduction synthesis reaction, and was 
observed to be slightly variable from synthesis to synthesis.  A broad optical spectrum centered 
around 420nm is expected for citrate-reduced silver particles in this size-range, the shoulder 
around 345nm being attributable to multipole resonance modes of the SNPs[22], absorbances 
above 550nm attributable the aggregates or larger rod-like structures[124]. Using a reported 







), the yield concentration of 60nm diameter citrate-reduced silver colloid was 
determined to be 50±10pM according to maximum SPR absorption. This may be compared to a 
theoretical yield of 72pM, based on complete reduction of silver colloid synthesized above. Once 
synthesized, the Ag colloid was stable for 2-3 weeks in dark conditions at 4°C.  
2.4.2 Naked and Functionalized SNP Characterization 
UV-Visible spectroscopy serves to probe changes in the SPR spectra of silver 
nanoparticles occurring with absorption of ligands at the particle surface, i.e. change in the 
dielectric environment [17, 29, 125]. Changes in the local dielectric environment around SNPs 
affect SPR spectra due to Mie Theory, which describes the extinction properties of small metal 
particles[19]. Salt aging functionalization techniques and absorption of ligands to the SNP 
surface results in damping of the SPR peak intensity and shifting of the peak resonance 
frequency, with an increase in the dielectric constant of the local environment typically causing a 
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red shift in the SPR absorption band[29]. This phenomenon has been observed in our synthesized 
SNP-oligo conjugates, with slight red-shifting of the SNP resonance peak providing evidence of 
ligand attachment to particle surfaces (Figure 2-5 a). SNP-conjugates also underwent a 4-5x 
decrease in concentration during functionalization as monitored by decrease in SPR absorbance 
intensity, but remained stable during subsequent treatments including centrifugation, 
resuspension, and UV-light exposure. 
 TEM analysis of non-functionalized and thiol-modified oligonucleotide functionalized 
SNPs (Figure 2-5 b&c) reveal an average „naked‟ SNP diameter of 68nm ± 20nm, and an 
average SNP-Thiol-oligo conjugate diameter of 74nm ± 20nm, based on particle counts (n = 50) 
and image analysis. Variegated SNP morphologies with a predominance of moderately sized 
rough spherical or spheroidal particles are characteristic of citrate ion reduction methods[126]. 
SNP-thiol oligo conjugates were observed to be surrounded with light interfering regions 
attributed to adsorbed oligonucleotides and associated salts (Figure 2-5 panel c) inset). TEM 
sample preparation, which involves dehydration of SNP and SNP-conjugates, and heating during 
imaging may affect surface tethered oligonucleotide layers. 
Fluorescence spectroscopy emission scans of naked SNPs vs. purified SNP-TYE-oligo 
conjugates (Figure 2-6) reveal the broad fluorescence properties of silver nanoparticles and 
conjugates when excited at 420nm. An excitation line at 420nm was chosen due to proximity to 
the maximum SPR absorbance peak of 60nm silver particles. Fluorescence emission spectra are 
also shown with an excitation line at 520nm, which provide evidence of TYE563-labeled oligo 




Figure 2-5 – Absorbance spectroscopy and TEM of SNPs and SNP-oligo conjugates. a) 
Normalized absorbance spectra for non-functionalized silver nanoparticles (SNPs) and thiol-
modified oligonucleotide functionalized silver nanoparticles. b) TEM images of naked (non-
functionalized silver nanoparticles and c) oligonucleotide-functionalized silver nanoparticles.  
 
 
Figure 2-6 – Fluorescence emission scans of SNPs vs. SNP-TYE-oligo conjugates at 420nm and 
520nm excitation lines. Black-dotted lines represent 420nm excited spectra, red-dotted lines 





2.4.3 DNA Coverage Quantification  
 Oligonucleotide coverage on the SNP-conjugate surface is an important aspect in terms 
of conjugate stability, efficiency of therapeutic delivery, and availability of attached 
oligonucleotides for hybridization[52]. Oligonucleotide loading density on nanoparticle surfaces 
is impacted by final salt concentration, oligonucleotide sequence, presence of spacers in mixed 
monolayers, and particle size/radius of curvature[57, 127].  A fluorescence-based method for 
quantifying oligonucleotide coverage on SNP surfaces, similar to that used by Demers el al[55], 




, with an 
oligonucleotide footprint[57] of 11.3±2 nm
2
. These values, calculated for 60nm diameter SNPs 
and a surface coverage ratio of 1000:1 oligonucleotide ligands per particle, are comparable to or 
higher than those reported previously for DNA-functionalized gold nanoparticles of similar 







, respectively) using PBS-buffer based salt-aging functionalization processes[57]. 
Complete DTT-mediated oligonucleotide removal[55] was confirmed via absorption 
spectroscopy analysis of colloid solutions, where DTT-mediated ligand removal promotes 
aggregation of silver nanoparticles and red-shifting of SPR spectra following ligand desorption.  
2.4.4 In Vitro Hybridization Activity 
In vitro hybridization studies reveal a caged phenomenon of SNP-tethered 
oligonucleotides. Oligos packed on the SNP surface are inactivated from their normal function, 
i.e. hybridization to a complementary target, until release and detachment from the particle 
surface.  Increases in molecular beacon fluorophore (5‟ FITC) fluorescence and quenching of 
TYE-labeled oligonucleotide fluorescence due to proximity to molecular beacon quencher (3‟ 
BHQ1) revealed an increase in availability of oligonucleotide ligand for hybridization to its 
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target sequence following chemical release from the SNP surface (Figure 2-7). Solution 
fluorescence measurements were taken in absence of silver nanoparticles, following chemical 
release of all ligand, due to interference of beacon emission and SNP emission at 520nm. 
Solution measurements were further confirmed via gel electrophoresis of particle-bound and 
DTT-released hybridized samples. Similar results were obtained showing an increase in 
hybridization following photo-release from SNP surfaces. The SNP in this case functions as a 
bulky caging group, inactivating the attached therapeutic nucleic acid until controlled, on-site 
photo-activation. 
 
Figure 2-7 – Hybridization of particle-bound vs. released oligonucleotide ligands. a) Graph of 
solution fluorescence data for FAM-labeled molecular beacon (MB) and TYE563-labeled thiol-
modified oligonucleotide. Sample 1 represents hybridization of a complementary MB to particle-
bound oligonucleotide, whereas sample 2 represents hybridization of a complementary MB to a 
released oligonucleotide, as measured by open-beacon FAM fluorescence and TYE quenching 
by the beacon‟s BHQ1.  b) Gel electrophoresis run of samples 1&2 in duplicate. 
  
2.4.5 In Vitro Protection from Nuclease Degradation 
Results from a DNase I digestion assay confirm previously proven phenomena of 
nuclease resistance for gold nanoparticle-tethered nucleic acids[5]. SNP-tethered TYE563-
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labeled oligonucleotides were effectively protected from nuclease action, as demonstrated by 
stability over time in the presence of DNase I for 0, 5, and 15min (Figure 2-8 bottom). Similarly 
treated TYE563-labeled oligonucleotide samples free in solution suffered significant nuclease 
degradation over the course of 15 min (Figure 2-8 top). TYE fluorescence measurements of 
aspirated solution following centrifugation of DNase I treated SNP-oligo conjugates also 
confirmed minimal nuclease degradation from nanoparticle surfaces (data not shown). 
 
Figure 2-8 – DNase I digestion assay of particle-bound vs. solution-phase oligonucleotides. a) 
Schematic of DNase I activity on solution-phase (top) and particle-bound (bottom) 
oligonucleotide. b) Gel electrophoresis run of nuclease digested solution-phase samples (top) and 
DTT-removed particle-bound samples (bottom) at 0, 5, and 15min nuclease treatment times.  
 
2.4.6 In Vitro Photo-release and Photo-release Efficiency 
In vitro studies confirmed the release of oligonucleotide ligands with internal NPE linkers 
from the surface of silver nanoparticles at photo-irradiation wavelengths between 302nm and 
365nm. UV-Vis spectra were monitored throughout functionalization, UV-light exposure, and 
DTT mediated release of oligonucleotide ligands from SNP surfaces (Figure 2-9 a). Slight red 
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shifting in flashed sample may be due to minimal particle aggregation due to exposure of 
concentrated SNP-conjugate samples to high UV-light doses in order to achieve efficient photo-
release in vitro, with aggregation mediated by possible joule heating in silver colloids. 
Exaggerated aggregation and SPR red shifting is expected for DTT-treated samples. 
Fluorescence data for SNP separated TYE563-labeled oligonucleotide ligands reveal effective 
purification (sample 2) and photo-release (sample 3) of ligands from SNP-oligo conjugates 
(Figure 2-9 b). 
The maximum yields of photo-release at both low (302nm) and high (356nm) wavelength 
ranges reached 50-60% of total ligand, based upon comparison of photo-released TYE563-
labeled oligonucleotide fluorescence intensity to that of subsequent DTT-released ligand, where 
DTT removes all remaining oligonucleotides following photo-exposure. Light dose-response 
plots reveal a traditional progression of photo-conversion over time for nitrophenylethyl-
containing photolabile oligonucleotides (Figure 2-10). Experimentally calculated functional 
quantum yields of SNP-tethered NPE linkers (Table 2-1) indicate that at a photo-irradiation 
wavelength of 302nm, a particle-to-NPE-linker distance of 2-3nm displays a higher quantum 
yield than the greater distances of 5-6nm particle-to-NPE-linker spacing for the 10mer linker 
oligo. Future studies are recommended for optimization of surface photochemistry and ligand 
photo-release. A functional quantum (𝛟fn) yield was deemed appropriate for evaluation of 
conversion of an oligonucleotide synthesized with an internal NPE linker into two separate 
oligonucleotide segments, as this is a measure of efficiency of ligand release from SNP-oligo 





Figure 2-9 – Photo-release from SNP surfaces. a) Normalized absorbance spectra for non-
functionalized silver nanoparticles (SNP), purified photo-sensitive SNP-oligo conjugates (Fluor 
SNP Purified), light-irradiated SNP-oligo conjugates (Fluor SNP Flash), and SNPs following 
DTT-mediated removal of surface oligonucleotides (Fluor SNP DTT). b) Graph fluorescence 
intensity for TYE-labeled oligonucleotide removed from nanoparticle surfaces via centrifugation 
(1 & 2), flashing (3), and DTT treatment (4). Inset: Gel electrophoresis run of samples 1,2,3 & 4.  
 
 
Figure 2-10 - Percent conversion of SNP-bound to photo-released oligonucleotide states.  
a) Comparison of NPE(10n)-oligo and TYE-NPE(1n)-oligo photorelease from the SNP surface 
at a photo-irradiation wavelength of 320nm b) Comparison of TYE-NPE(1n)-oligo photorelease 
from the SNP surface at a photo-irradiation wavelengths of 320nm and 365nm. 
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Table 2-1 - Photocleavage properties of SNP-bound photolabile oligonucleotides 
 
 
2.4.7 Confocal Microscopy Analysis of SNP-conjugate Delivery and Photo-release Profile  
Confocal microscopy results display effective intracellular delivery of SNP-
oligonucleotide conjugates and photo-release of oligonucleotide ligands in situ. Delivery of SNP-
oligo conjugates to the intracellular environment was achieved without the use of extraneous 
transfection vectors (Figure 2-11, SNP-oligo conjugate images 3a,b,c,d). This is opposed to 
naked DNA oligonucleotides, which traditionally require a transfection carrier such as a cationic 
lipid or polymer to facilitate intracellular delivery (Figure 2-11 TYE-oligo + TurboFect images 
4a,b,c,d). Localization of SNP-oligo conjugates in the intracellular space was confirmed via 3-
dimensional reconstruction of thin-slice confocal image stacks (supplemental information Figure 
2-15- Figure 2-16). Overlay of particle reflectance at 488nm with TYE-labeled oligonucleotide 
fluorescence (549nm/563nm) indicates co-localization of oligonucleotide ligand with SNPs in 
the absence of UV-light exposure (Figure 2-11 3c). Naked SNPs were also observed to achieve 
high levels of cellular uptake, making the argument for transmembrane transportation based 
primarily on the properties (size, morphology) of silver nanoparticles alone. Naked and 
functionalized SNPs were found to reside primarily in the cytosolic environment of treated HeLa 
cells, as opposed to other areas not desired in mRNA-targeting antisense applications, such as 





Figure 2-11 - SNP-Fluor oligo conjugate delivery to HeLa cells. Control (1) vs. naked SNP 
treated (2) vs. SNP-TYE-oligo conjugate treated (3) vs. TYE-oligo treated (4) HeLa cells. 
Images depict  (a) silver particle fluorescence (488nm/520nm), (b) TYE fluorescence 
(549/563nm), (c) Reflectance + Fluorescence overlay , and (d) Brightfield views.  SNPs exhibit a 
wide range of fluorescence emission, explaining appearance of faint silver signal in the TYE563 
channel (2b).  
 
Intracellular redistribution of labeled oligonucleotides upon photo-exposure of SNP-oligo 
conjugates was also demonstrated via confocal microscopy (Figure 2-12). In all non-photo-
exposed samples, TYE-labeled oligonucleotide fluorescence co-localized with silver 
nanoparticle fluorescence (Figure 2-12 panel 1a,b,c), in a punctuate pattern within the cell (see 
schematic I in Figure 2-12). Particle fluorescence is demonstrated in green for ease of 
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visualization of overlay (yellow) regions. Co-localization of TYE563 and silver fluorescence 
indicates that conjugates are stable and remain intact after 16-24hrs within a cellular 
environment. However, upon UV-irradiation of cells treated with photo-sensitive SNP-oligo 
conjugates, a diffusion of oligonucleotide fluorescence (Figure 2-12 panels 2,3) reflects release 
of functional ligands from particle surfaces and implicates increased availability of these 
oligonucleotides for binding to mRNA targets within the cytosol. Sequestration of 
oligonucleotides within the nucleus, often observed for cells loaded with oligonucleotides via 




Figure 2-12 – Photo-released SNP-Fluor oligo conjugates.  I. Schematic of intracellular particle-
bound oligonucleotide ligand (a) vs. photo-released ligand (b).  II. Non-released (1) vs. photo-
released (2,3) ex vivo SNP-fluor conjugates samples.  Images depict (a) Particle fluorescence 




2.4.8 Antisense Activity of SNP-oligo Conjugates  
Confocal microscopy results display the successful delivery and caging effect of silver 
nanoparticle carriers for antisense DNA oligonucleotides. SNP-bound ISIS 2302 antisense 
oligonucleotides, which target ICAM-1(CD54) mRNA, were shown to decrease the expression 
level of INF-γ upregulated CD54 upon external photo-activation, i.e. photo-release from silver 
particle surfaces within the intracellular environment (Figure 2-13). Successful knockdown is 
evidenced by reduced membrane labeling of a primary mouse anti-human CD54 APC-
conjugated antibody in photo-exposed, SNP-oligo conjugate treated HeLa cells. This reduced 
labeling is apparent when we compare non-flashed (2d) and flashed (3d, 4d) cases, where cell 
membrane staining with APC (yellow) is indicative of CD54 expression levels. Diffuse, SNP 
photo-released TYE-oligo can be seen as diffuse cytosolic fluorescence delineated on the cell 
periphery by faint antibody staining (3d, 4d). It is important to note that the appearance of 
broadly fluorescent nanoparticles in the APC emission images can be differentiated from 
membrane antibody staining due to differences in localization. Overlay of SNP and TYE 
emission appears magenta, whereas overlay of SNP, TYE, and APC emission appears white. 
Naked SNPs at similar loading concentrations were shown to have no effect on CD54 expression 
in both non-UV-exposed and UV-exposed cases (data not shown). Non-caged free solution 
TYE-oligo was used as a control, loaded at high concentrations via TurboFect polymer 
transfection agent. Limited APC staining is apparent in these control samples, providing 






Figure 2-13 – Antisense activity of photo-activated SNP-TYE-oligo conjugates. CD54-
expressing HeLa cells without antisense treatment (1) are compared to SNP-TYE oligo conjugate 
treated cells in both non-activated (2) and photo-activated (3, 4) cases. TurboFect (TF) 
transfected TYE-oligo treated HeLa cells (5) are used as a control case. Images depict (a) silver 
particle fluorescence (488/520nm), (b) TYE fluorescence (549/563nm), (c) APC-conjugated 
anti-human CD54 fluorescence (633/680), (d) fluorescence overlay, and (e) Brightfield views.  
SNPs exhibit a wide range of fluorescence emission, explaining appearance of faint silver signal 
in the TYE563 channel (2b). 
 
2.5 Discussion 
The synthesis and in vitro/intracellular characterization of UV-photo-activated silver 
nano-carriers of antisense therapeutics has been accomplished. Moderately sized silver 
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nanoparticles (60nm in average diameter) were shown to be easily functionalized with thiol-
capped nitrophenylethyl (NPE) photocleavable linker-containing oligonucleotides. The 
photochemistry of NPE was found to be fully functionally at traditional UV wavelengths when 
tethered close to optically active SNP surfaces. The enhancement factor of absorption, 
fluorescence, scattering, or photochemistry of any chromophore or photochemical compound at 
or near a silver surface will depend on particle shape and size, as well as the distance of the 
photoactive molecule from the particle surface[36]. The size factor was considered in our 
selection of appropriate SNP sizes for maximum efficiency of ligand fluorescence detection and 
nitrophenylethyl (NPE) photochemical processes near silver surfaces. Moderately sized particles 
(~50nm in diameter) have been found previously to display the most enhanced intensity of local 
fields and surface enhanced fluorescence (SEF)[31]. The distance factor is of particular 
importance in relation to photochemical processes of molecules directly adsorbed or tethered a 
short distance from the metal surface (<1nm), where the effective transfer of energy from the 
excited molecule to the metal surface, i.e. quenching, competes with the accumulation of energy 
by the molecule, often enhanced due to interaction with the surface[41]. Thus an important 
consideration in our studies on photo-release of therapeutics from silver surfaces was tailoring 
the distance of the NPE photo-cleavable linker from the SNP surface in order to strike a 
compromise between field enhancement (i.e. enhanced photochemistry) and nonradiative 
damping[9] or quenching processes. A separation of ~2-3nm has been found appropriate for 
efficient release of SNP-tethered oligonucleotide therapeutics using UV-light exposure doses 
non-toxic to a treated endothelial cell line. Distance-dependent photoreactivity of SNP-tethered 
photocleavable linkers could be further elucidated by a complete investigation of various 
particle-to-NPE-linker distances to determine optimal oligo design for photorelease. Optimal 
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distances for surface-enhanced photochemistry will depend on compound reaction rates and 
nonradiative decay rates to the metal surface[121]; orientation of photoactive compounds to the 
surface[128], and properties of the particles themselves including size and morphology[32]. 
However, favorable distances will theoretically reside within a range proportionate to the 
substrate particle radius, due to significant decay of near-field enhancements beyond this range. 
We have used to our advantage the characterized broad range of SNP optical properties, 
including fluorescence in a standard FITC channel, for detection and confirmation of SNP-
antisense conjugate delivery and intracellular drug release. The SNP-based delivery platform was 
shown to not only provide nuclease resistance of transported antisense therapeutics, but also 
enhance the cellular uptake and intracellular diffusion of their nucleic acid ligands upon photo-
release from particle surfaces. The light-triggered increase in cytosolic distribution indicates 
augmented availability of oligonucleotide therapeutics for hybridization to mRNA targets, 
revealed by SNP-conjugate photo-activated ISIS2302 antisense activity against Intracellular 
Adhesion Molecule-1 (ICAM-1), a membrane protein over-expressed in the presence of 
particular cytokines in HeLa cells ([129]). Delivery enhancements, it is important to note, were 
accomplished in the absence of additional transfection vectors. Efficiency of SNP-mediated 
delivery of antisense oligonucleotides to the intracellular environment was found to vie with that 
of a commercial standard polyethylenimine-based transfection agent, considering factors 
including amount, rate, and ease of drug delivery. These results corroborate previous studies 
showing enhanced delivery of SNP-oligo conjugates into cellular environments based on dense 
surface charges, associated salts, and adsorbed proteins in serum medias, with internalization 
exaggerated upon increasing oligonucleotide surface loading density. Cell culture assays 
demonstrate, in addition to successful delivery and release of SNP-bound antisense therapeutics, 
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effective caging of antisense activity for oligonucleotides attached to SNP surfaces in the 
absence of external photo-activation cues, whereupon therapeutic activity was restored. These 
silver nano-composite caging systems permit photo-controlled activation of gene silencing. With 
the advancement of new delivery agents and controlled targeting/release methods a prized goal 
in nanomedicine and antisense gene therapy technology[16], a novel silver antisense nano-carrier 
for photo-activated gene silencing holds high impact as a promising alternative to existing drug 
delivery platforms. New light-sensitive intelligent drug delivery systems are also of high interest, 
and our synthesis of a silver nano-conjugate caging platform for antisense oligonucleotides is a 
step in the direction toward multicomponent nano-systems for smart drug delivery with 
improved mechanical properties and precisely controlled activity in vivo[68]. The technology 
promises high impact in the fields of nanomedicine and antisense gene therapy. 
2.6 Supplemental Information  
2.6.1 Surface Coverage Quantification: TYE-oligo Calibration 
SNP-oligo conjugate surface coverage was quantified using fluorescence calibrations 
(Figure 2-14) of TYE-NPE(1n)-oligo at known concentrations. Oligonucleotide at given 
concentrations in 100ul volumes were analyzed for fluorescence intensity values (540/563nm). 
These values were then used to evaluate experimental quantities of DTT-removed 
oligonucleotides from functionalized SNP surfaces. 
2.6.2 SNP-Conjugate Delivery: Confocal 3D Reconstruction 
 Confocal z-direction stacks were taken of SNP-TYE-oligo conjugate treated cells in order 
to verify intracellular localization. Select slices are shown (Figure 2-15) which confirm that 
particles are located in the cytosolic environment of imaged cells. 3D reconstruction rotating 
images are also provided which reveal the three-dimensional SNP-oligo conjugate delivery 
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throughout a treated HeLa cell (Figure 2-16).  Images were taken using a Leica DM IRE2 
inverted microscope with a galvo-Z stage. Images were compiled and rendered into 3-
dimensional projections using Leica Lite software. 
 
Figure 2-14 – TYE-oligo calibration curve for surface coverage quantification  
 
 
Figure 2-15 - Confocal stacks of HeLa cells treated with SNP-TYE-oligo conjugates. Shown are 
stack (1-11) and all-layer projection (12) images. Images depict a) brightfield and b) TYE 




Figure 2-16 - Confocal 3D images of a single HeLa cell treated with SNP-TYE-oligo 
conjugates. Shown are stack (1-9) images which depict a) SNP emission (480/520nm) and b) 
TYE emission (549/563nm) views. 
 
2.7 Conclusion 
In conclusion, we have synthesized and characterized antisense silver nano-conjugates for 
enhanced delivery of antisense therapeutics and photo-activated gene silencing. Our designed 
SNP-oligo conjugates display desirable properties as drug delivery agents both in vitro and ex 
vivo. We hope in future studies to further characterize oligonucleotide linker photochemistry and 
the effect of SNP surface-enhancement properties on this chemistry, as well as investigate multi-
component SNP-conjugate systems with increased protection and photo-activated antisense 
activity against a variety of gene targets. We believe our studies have contributed significantly to 
the investigation of metal nano-composites as improved drug delivery vehicles and antisense 
therapeutics. The developed technology may be used in laboratory settings for gene expression 
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Chapter 3. Conclusions and Future Work 
 
3.1 Conclusion 
We have accomplished the synthesis and in vitro/ex vivo characterization of a novel antisense 
drug delivery platform for photo-activated gene therapy based on silver nanoparticle composites. 
Important goals of the thesis project included: surface functionalization of SNPs with photolabile 
antisense oligonucleotides and characterization of composite stability, surface coverage, ligand 
protection, and photo-activation efficiency; optimization of surface photochemistry; evaluation 
of delivery and subcellular localization of silver nano-composites ex vivo; and finally 
investigation of light-triggered antisense activity of SNP-conjugates against ICAM-1 in a 
fluorescence detection based gene silencing assay in HeLa cells. The results of these 
experimental objectives give weight to the exploration of silver nano-composites as potent 
platforms for photo-activated gene silencing with unique optical properties and potential for 
surface-enhanced photo-release capabilities. Densely packed SNP-antisense conjugates where 
shown to provide protection to attached antisense DNA oligonucleotides, inactivating or „caging‟ 
the nucleic acid ligands until light-triggered release of the active therapeutics from silver 
surfaces. Silver nanoparticle drug delivery conjugates were found to be non-toxic at sufficiently 
high concentrations to provide effective antisense activity. Our demonstration of silver 
nanoparticles in drug delivery and gene therapy applications is groundbreaking due to a previous 
bias against use of silver nanomaterials in these fields of study. We hope to pursue our research 




3.2 Future Work 
We hope to complete our studies on the silver nanoparticle antisense composites we have 
described with several investigations ranging from in vitro to in vivo characterization. The 
following investigations are proposed: 
3.2.1 Long-term Effects of Oligonucleotide Silver Nano-composites on Cell Health.  
Experiments will include viability studies on naked SNP and SNP-conjugate treated HeLa 
cells out to 48hr treatment times. We expect limited toxicity based on preliminary cell health 
analysis based on morphology of SNP exposure cells. Data will include fluorescent staining 
indicative of cell death or membrane compromised states, analyzed via confocal microscopy or 
flow cytometry.  
3.2.2 Comparison of Silver Surface Tethered NPE (Nitrophenylethyl) Linker 
Photochemistry to That of NPE Compounds in Solution.  
Methods will include HPLC analysis of TYE-NPE(1n)-oligonucleotide photo-cleavage in 
solution phase. HPLC will be required to discriminate between a 30mer intact oligo and photo-
cleaved 29mer + 1mer components. 
3.2.3 A Complete Study of NPE-mediated Ligand Photorelease Efficiency at Variable 
Particle to-NPE Linker Distances and Irradiation Wavelengths.  
These investigations will help to evaluate the possibility of SNP surface-enhanced 
photocleavage and oligonucleotide photo-release at traditional ultraviolet as well as red-shifted 
excitation wavelengths. This potential surface-enhancement of photochemistry will be silver 
surface distance-dependent, requiring a fine tuning of NPE linker location along an SNP-
attached oligonucleotide backbone. 
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3.2.4 Investigation of Various Fluorescence-independent Reporter Genes for Antisense 
Activity Evaluation (eg Luciferase).  
As has been demonstrated in our results on naked SNP vs. SNP-oligonucleotide 
conjugate characterization, silver nanoparticles has significant fluorescence in a wide range of 
excitation and emission wavelengths. This characteristic can be problematic for multi-channel 
fluorescence-based detection assays, and can lead to reduced detection limit due to a base-line 
signal from fluorescent particles. Thus we propose to investigate alternative reporter gene 
systems for antisense activity evaluation of SNP-oligo conjugates in future work. These reporter 
genes may be chemical or phosphorescent in nature (ex. Luciferase), allowing for greater 
flexibility and improved detection limits in assays with fluorescent silver nanocomposites.    
3.2.5 In Vivo Studies of Uptake and Fate of Injected SNP-antisense Conjugates. 
We hope to further characterize our system for in vivo applications in future studies. We 
propose investigations on uptake and fate of SNP-antisense conjugates following injection in in 
vivo tissues. These will be performed in a suitable animal model, and fluorescent silver nano-
conjugates may serve as biological labels for tracking injected samples. 
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Appendix. Materials and Protocols 
A.I. Cell Culture Protocol 
HeLa Splitting and Seeding Procedure  
A. Feeding  
1) Aspirate media  
2) Add 5ml of fresh DMEM-RS+3%Fetal Bovine Serum per T-25 flask (doubling time = 24hrs) 
3) Feed once a week for T-25 flask  
 
B. Splitting cells (volumes are per one T-25 of confluent HeLa‟s)  
1) Aspirate media from flask to waste  
2) Rinse w/ 5 ml CMF-PBS (Ca+ & Mg+ free) and swivel in flask  
3) Aspirate off PBS to waste  
4) Add 5 ml of Trypsin solution  
a. Wait ~10 minutes for cells to come off of the dish at room temperature. Gently rock 
flask periodically and observe under microscope to make sure the cells are detaching  
5) Add 5 ml of DMEM-RS+3%FBS to inactivate trypsin  
6) Transfer suspension to a 50ml centrifuge tube.  
7) Spin down the cells at 1800rpm for 5 min on the centrifuge (Eppendorf 5702)  
8) Decant supernatant  
9) Resuspend in 5ml of DMEM-RS+3%FBS  
a. For Passaging:  
i. Add 5ml fresh DMEM-RS+3%FBS to a new T-25 flask  
ii. Add 3-5 drops of the cell suspension in the new T-25 flask for flask passaging 
b. For Experiment:  
i. Dilute cell media (1ml into 9ml fresh media) and seed 500ul diluted cell 
solution into 8-well chambered wells (LabTek chambered Slides, NUNC)  
 
A.II. Cell Transfection Protocol 
A. Transfection Protocol 
1) Add TrojanPorter to100ul of  SFM (serum-free media) and  incubate for 5min at RT 
2) Complex DNA & TrojanPorter for ~15min at RT 
3) Add polyplexes directly to 500ul of cell media in 8-well chambers  transfect for 16-24 hrs 
A.III. Confocal Imaging Protocol 
  A. Confocal Protocol  
1) Start-up: (Turn on laser fan and Ar/He laser key, allow lasers 15min for warm-up before use) 
2) Start PC and turn on scanner 
3) Turn on additional lasers if needed  
4) Adjust laser intensity via knob on front panel (to ~ 40%)  
5) Turn on microscope mercury lamp  
6)  Start-up Leica Software  
i. Open Beam control window: choose emission windows and gain settings  
ii. In confocal software, use Z-scan button to change to Z-wide  
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iii. Automatically change to oil objective (40x default)  
iv. Switch to Visual for viewing on scope ; Scan for imaging  
v. Adjust laser intensity: start w/ low intensity (~20% or less) and adjust as necessary  
vi. Adjust PMT gains (appropriate range 500-800) for all emission channels  
7) Shut Down Procedure  
i. Turn off microscope lamp  
ii. Turn off lasers (MUST be turned off 15min prior to turning off laser fan)  
iii. After 15min, turn off laser fan, scanner, and PC  
 
A.IV APC-Antibody Staining Protocol 
A. Antibody Staining (@16hrs post treatment) 
1) aspirate cell media 
2) wash in 500ul CMF PBS + 2% BSA 
3) resuspend in 200ul OptiMem + 2% BSA 
4) add 10ul APC-Anti-Human CD54 antibody to each well (leave 1hr in dark) 
5) wash in 500ul CMF-PBS 
6) resuspend in 500ul OptiMem for confocal imaging 
 
A.V Hybridization Assay Protocol 
A. In Solution Hybridization Assay Protocol (samples in duplicate) 
Non-released Sample: 
1) Purify TYE-SNPs (500ul): 1 x 20min @7000RPM 
2) Add MB (5ul 1/10dil) & Hyb (conditions = 15min 60degC + 5min RT + 5min 4degC) 
3) Purify unbound MB from fluor-SNPs (1 x 20min @7000RPM) 
4) Release via DTT  purify released oligo/duplex from SNPs (centrifuge & amicon)  
measure fluorescence and run gel (compare ssDNA vs. oligo-MB duplex) 
 
Released Sample: 
1) Purify TYE-SNP (500ul)  
2) Release via flashing (6min GS)  
3) Add MB (5ul of 1/10dil) and Hyb (conditions = 15min 60degC + 5min RT + 5min 4degC) 
3) Purify unbound MB/duplex from flashed fluor-SNPs (1 x 20min @7000RPM) 
5) Release via DTT  purify released oligo/duplex from SNPs (centrifuge & amicon)  
measure fluorescence and run gel (compare ssDNA vs. oligo-MB duplex) 
A.VI. Nuclease Digestion Assay 
A. Nuclease Assay for SNP-oligo conjugates 
1) Purify SNP-oligo conjugates and resuspend in DNase I NEB buffer 
2) Prepare TYE-oligo solution in DNase I buffer (3 samples) 
3) Add DNase I to sample solutions – incubate at 37degC for digestion intervals 
4) Add STOP buffer (EDTA) to inactivate DNase I 
5) Purify digested SNP-oligo conjugates (1x) 
6) DTT-remove oligo from SNP-oligo conjugates 





A.VII. SNP Synthesis Protocol  
A. SNP Synthesis 
1) Thorough cleaning of all glassware with ethanol 
2) Add .09g silver nitrate to 500ml DI water in large beaker 
3) Add .3g sodium citrate (1%) to 30ml DI water in small beaker 
4) Bring silver nitrate to boil while stirring (95 deg C) 
5) Add 10ml of 1% citrate at a rate of 0.5ml/min (dropwise) 
6) Color will change at 2ml of added citrate (pale yellow) 
7) Color will change at 5ml of added citrate (dark green) 
8) Let solution boil 10min after addition of 10ml citrate 
9) Cool solution to RT and quickly transfer to fridge in air-tight, dark conditions 
 
A.VIII. SNP Functionalization Protocol  
 
A. Reagents 
1) Thiol-Oligo: MW = 9349.2g/mol; Amount of Oligo: 155.8nmoles = 1.46mg; Stock : 4ug/ul = 
1460ug/365ul = 426.849315uM 
2) TYE-NPE(1n)-Oligo: MW = 10184 g/mol; Amount of Oligo: 91.6nmoles = .93mg;  
Stock : 4ug/ul = 930ug/232ul = 392.688172uM 
3) PC-NPE(1n)-Oligo: MW = 9693.5g/mol; Amount of Oligo: 117.2nmoles = 1.14 mg; Stock : 
4ug/ul = 1140ug/285ul = 411.2280702uM 
B. 4500:1 oligo to nanoparticles ratio; 1ml 72pM colloid = 7.2 x10
14
 mol nanoparticles; 0.324uM 
Oligo per 1ml silver colloid 
C. Protocol 
1) Add Thiol-modified or cyclic-disulfide-modified oligonucleotides to citrate-stabilized silver 
nanoparticles (~ .324 nmoles oligonucleotide per 1 ml of 72 pM colloid) 
2) After 3hrs, add 10ul of 10% SDS, 25ul phosphate buffer (0.1 M; pH = 7.4) to bring the mixture 
to 0.0025 M phosphate 
3) After 12hrs, begin salt aging process: in 4hr intervals add 10ul aliquots of Tris-NaCl buffer 
(2M in DI water, pH = 8 – 8.5) to a final concentration of 160-200mM Tris-NaCl (8-10 additions 
of 10ul aliquots) or until conjugate colloid is fading due to functionalization (to lighter golden 
color) 
4) Rock resulting mixture gently (lowest speed) over course of 48hrs 
5) Purification via centrifugation (3x 7000RPM) 
6) Pull supernatant off SNP pellet and resuspend in dilute (100mM) Tris-NaCl Buffer + 10%SDS 
 
A.IX. Materials and Reagents 
 SNP Synthesis Reagents: 
 1) Silver nitrate – lab bench (Ammar) 
 2) Sodium citrate – lab bench (Ammar) 
 3) Nanoparticle solutions – old fridge 
 4) All glassware/stirbars for synthesis – Ammar lab bench 
 5) Tris-NaCl salt buffer and other salt solutions – cabinet in microfab room  
  
 Transfection Reagents: 
 1) TurboFect (stock solution in main grad fridge – bottom door shelf) 




 DNA/Oligo Stocks: 
 1) Grad/Ugrad Freezer (top shelf, in labeled IDT packages; in Paige‟s Oligo Stocks) 
 
 ICAM-1 Assay Reagents: 
 1) INF-y (3/2010 stock) – Freezer top shelf, Paige‟s Stocks) 
 2) AbCam APC-labeled Antibody – Main grad fridge top shelf in original packaging 
 
 Flashing cuvette: Paige‟s cabinet in microfab room (2
nd
 shelf from bottom in black case) 
 Blue/Green Bandpass filters for GreenSpot – on cart with GS  
 
 Other Fluorophores: 
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